<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Harm Reduct J</journal-id><journal-id journal-id-type="iso-abbrev">Harm Reduct J</journal-id><journal-id journal-id-type="pmc-domain-id">242</journal-id><journal-id journal-id-type="pmc-domain">harmred</journal-id><journal-title-group><journal-title>Harm Reduction Journal</journal-title></journal-title-group><issn pub-type="epub">1477-7517</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11344336</article-id><article-id pub-id-type="pmcid-ver">PMC11344336.1</article-id><article-id pub-id-type="pmcaid">11344336</article-id><article-id pub-id-type="pmcaiid">11344336</article-id><article-id pub-id-type="pmid">39182116</article-id><article-id pub-id-type="doi">10.1186/s12954-024-01062-2</article-id><article-id pub-id-type="publisher-id">1062</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Strategies used to reduce harms associated with fentanyl exposure among rural people who use drugs: multi-site qualitative findings from the rural opioid initiative</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Walters</surname><given-names initials="SM">Suzan M.</given-names></name><address><email>suzan.walters@nyulangone.org</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Baker</surname><given-names initials="R">Robin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Frank</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fadanelli</surname><given-names initials="M">Monica</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rudolph</surname><given-names initials="AE">Abby E.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zule</surname><given-names initials="W">William</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fredericksen</surname><given-names initials="RJ">Rob J.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bolinski</surname><given-names initials="R">Rebecca</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sibley</surname><given-names initials="AL">Adams L.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Go</surname><given-names initials="VF">Vivian F.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ouellet</surname><given-names initials="LJ">Lawrence J.</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pho</surname><given-names initials="MT">Mai T.</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seal</surname><given-names initials="DW">David W.</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Feinberg</surname><given-names initials="J">Judith</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Smith</surname><given-names initials="G">Gordon</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Young</surname><given-names initials="AM">April M.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stopka</surname><given-names initials="TJ">Thomas J.</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0190ak572</institution-id><institution-id institution-id-type="GRID">grid.137628.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8753</institution-id><institution>Department of Population Health, </institution><institution>New York University Grossman School of Medicine, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/049s0rh22</institution-id><institution-id institution-id-type="GRID">grid.254880.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2179 2404</institution-id><institution>Learning Design and Innovation, </institution><institution>Dartmouth College, </institution></institution-wrap>Hanover, NH USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0190ak572</institution-id><institution-id institution-id-type="GRID">grid.137628.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8753</institution-id><institution>Department of Social and Behavioral Health, School of Global Public Health, </institution><institution>New York University, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03czfpz43</institution-id><institution-id institution-id-type="GRID">grid.189967.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7398</institution-id><institution>Rollins School of Public Health, </institution><institution>Emory University, </institution></institution-wrap>Atlanta, GA USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00kx1jb78</institution-id><institution-id institution-id-type="GRID">grid.264727.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2248 3398</institution-id><institution>Department of Epidemiology and Biostatistics, </institution><institution>Temple University College of Public Health, </institution></institution-wrap>Philadelphia, PA USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/052tfza37</institution-id><institution-id institution-id-type="GRID">grid.62562.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 0030 1493</institution-id><institution>RTI International, </institution></institution-wrap>Research Triangle Park, NC USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00cvxb145</institution-id><institution-id institution-id-type="GRID">grid.34477.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2298 6657</institution-id><institution>Department of Medicine, </institution><institution>University of Washington, </institution></institution-wrap>Seattle, WA USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.411026.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 1090 2313</institution-id><institution>Southern Illinois University, </institution></institution-wrap>Carbondale, IL USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Department of Health Behavior, Gillings School of Global Public Health, </institution><institution>University of North Carolina-Chapel Hill, </institution></institution-wrap>Chapel Hill, NC USA </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02mpq6x41</institution-id><institution-id institution-id-type="GRID">grid.185648.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2175 0319</institution-id><institution>Division of Epidemiology and Biostatistics, School of Public Health, </institution><institution>University of Illinois Chicago, </institution></institution-wrap>Chicago, IL USA </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/024mw5h28</institution-id><institution-id institution-id-type="GRID">grid.170205.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7822</institution-id><institution>Department of Medicine, </institution><institution>University of Chicago, </institution></institution-wrap>Chicago, IL USA </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.265219.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2217 8588</institution-id><institution>Social, Behavioral, and Population Sciences, </institution><institution>Tulane University School of Public Health and Tropical Medicine, </institution></institution-wrap>New Orleans, LA USA </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.268154.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2156 6140</institution-id><institution>Departments of Behavioral Medicine and Psychiatry and Medicine/Infectious Diseases, School of Medicine, </institution><institution>West Virginia University, </institution></institution-wrap>Morgantown, WV USA </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/011vxgd24</institution-id><institution-id institution-id-type="GRID">grid.268154.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2156 6140</institution-id><institution>Department of Epidemiology and Biostatistics, School of Public Health, </institution><institution>West Virginia University, </institution></institution-wrap>Morgantown, WV USA </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02k3smh20</institution-id><institution-id institution-id-type="GRID">grid.266539.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8438</institution-id><institution>Department of Epidemiology and Environmental Health, </institution><institution>University of Kentucky College of Public Health, </institution></institution-wrap>Lexington, KY USA </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05wvpxv85</institution-id><institution-id institution-id-type="GRID">grid.429997.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7531</institution-id><institution>Department of Public Health and Community Medicine, </institution><institution>Tufts University School of Medicine, </institution></institution-wrap>Boston, MA USA </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>21</volume><issue-id pub-id-type="pmc-issue-id">452341</issue-id><elocation-id>154</elocation-id><history><date date-type="received"><day>15</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>17</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>08</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>24</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-29 04:25:15.117"><day>29</day><month>08</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12954_2024_Article_1062.pdf"/><abstract id="Abs1"><sec><title>Aim</title><p id="Par1">Illicitly manufactured fentanyl and its analogs are the primary drivers of opioid overdose deaths in the United States (U.S.). People who use drugs may be exposed to fentanyl or its analogs intentionally or unintentionally. This study sought to identify strategies used by rural people who use drugs to reduce harms associated with unintentional fentanyl exposure.</p></sec><sec><title>Methods</title><p id="Par2">This analysis focused on 349 semi-structured qualitative interviews across 10 states and 58 rural counties in the U.S conducted between 2018 and 2020. Interview guides were collaboratively standardized across sites and included questions about drug use history (including drugs currently used, frequency of use, mode of administration) and questions specific to fentanyl. Deductive coding was used to code all data, then inductive coding of overdose and fentanyl codes was conducted by an interdisciplinary writing team.</p></sec><sec><title>Results</title><p id="Par3">Participants described being concerned that fentanyl had saturated the drug market, in both stimulant and opioid supplies. Participants utilized strategies including: (1) avoiding drugs that were perceived to contain fentanyl, (2) buying drugs from trusted sources, (3) using fentanyl test strips, 4) using small doses and non-injection routes, (5) using with other people, (6) tasting, smelling, and looking at drugs before use, and (7) carrying and using naloxone. Most people who used drugs used a combination of these strategies as there was an overwhelming fear of fatal overdose.</p></sec><sec><title>Conclusion</title><p id="Par4">People who use drugs living in rural areas of the U.S. are aware that fentanyl is in their drug supply and use several strategies to prevent associated harms, including fatal overdose. Increasing access to harm reduction tools (e.g., fentanyl test strips, naloxone) and services (e.g., community drug checking, syringe services programs, overdose prevention centers) should be prioritized to address the polysubstance-involved overdose crisis. These efforts should target persons who use opioids and other drugs that may contain fentanyl.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12954-024-01062-2.</p></sec></abstract><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000026</institution-id><institution>National Institute on Drug Abuse</institution></institution-wrap></funding-source><award-id>K01DA053159</award-id><award-id>UG3 DA044831</award-id><award-id>5UH3DA044798</award-id><award-id>4UH3DA044380</award-id><award-id>UH3DA044823</award-id><award-id>U24DA048538</award-id><award-id>5UH3DA044822</award-id><award-id>4UH3DA044829-03</award-id><award-id>5UH3DA044822</award-id><award-id>5UH3DA044826</award-id><award-id>UH3DA044830</award-id><principal-award-recipient><name name-style="western"><surname>Walters</surname><given-names>Suzan M.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>Robin</given-names></name><name name-style="western"><surname>Fadanelli</surname><given-names>Monica</given-names></name><name name-style="western"><surname>Zule</surname><given-names>William</given-names></name><name name-style="western"><surname>Fredericksen</surname><given-names>Rob J.</given-names></name><name name-style="western"><surname>Bolinski</surname><given-names>Rebecca</given-names></name><name name-style="western"><surname>Go</surname><given-names>Vivian F.</given-names></name><name name-style="western"><surname>Seal</surname><given-names>David W.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">The United States continues to experience the worst overdose epidemic in the world [<xref ref-type="bibr" rid="CR1">1</xref>]. The COVID-19 pandemic has exacerbated this situation; there was a 31% increase in overdose deaths (including those attributed to synthetic opioids and stimulants, such as cocaine and methamphetamine) from 2019 to 2020 [<xref ref-type="bibr" rid="CR2">2</xref>] and a further 14% in 2021 [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>], with deaths exceeding 100,000 in 2021 and 2022 [<xref ref-type="bibr" rid="CR5">5</xref>]. The primary driver of opioid overdose deaths in the U.S. is illicitly manufactured fentanyl [<xref ref-type="bibr" rid="CR6">6</xref>], a synthetic opioid approximately 50 times more potent than heroin [<xref ref-type="bibr" rid="CR7">7</xref>]. Recent data point to a drug supply that is largely contaminated with fentanyl [<xref ref-type="bibr" rid="CR8">8</xref>]. In the absence of drug checking, people who use drugs are at increased risk for drug poisoning, which can happen intentionally or unintentionally when drugs are unknowingly adulterated [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Although some people who use drugs are aware they are using fentanyl, a large proportion of the overdose burden is attributed to unintentional use, as many illicit substances, including both opioids and stimulants, are adulterated with fentanyl of unknown concentration [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Recent research has documented a growing number of people who use more than one drug (e.g., polysubstance use) experiencing overdose [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par6">There have historically been variations in overdose mortality rates and fentanyl proliferation across US regions. In 2016, states with the highest opioid death rates included West Virginia, New Hampshire, Ohio, Maryland, and Massachusetts [<xref ref-type="bibr" rid="CR12">12</xref>]. The populations and regions most impacted by fatal overdose and the types of drugs involved have changed over time. For example, between 2016 and2018, white populations experienced a statistically significant decrease in overdose deaths while overdose deaths began to increase among Black populations [<xref ref-type="bibr" rid="CR13">13</xref>]. Similar increases in fatal overdoses have been occurring in Hispanic populations [<xref ref-type="bibr" rid="CR14">14</xref>]. Fatal overdose death rates were also higher in areas with greater income inequality and a larger proportion of Black residents [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par7">Between 2015 and 2016, Eastern states had the largest increase in synthetic opioid overdose deaths, while the Midwest saw the largest increase in psychostimulant-involved overdose deaths. Then, from 2018 through 2019, synthetic opioid overdose deaths increased in the west, while psychostimulant-involved overdose deaths increased in the Northeast [<xref ref-type="bibr" rid="CR16">16</xref>]. Finally, the COVID-19 pandemic has exacerbated overdose mortality overall, resulting in sharp increases of fatal overdoses, widening social and economic disparities, and decreased access to resources [<xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par8">Given the extensive literature on overdose prevention in urban areas with greater access to resources including harm reduction, it is important to understand whether and how the measures/strategies people who use drugs in geographically diverse rural settings take to protect themselves. Health-related practices that urban people who use drugs enact to embed safety and risk reduction in their networks has long been an endogenous practice [<xref ref-type="bibr" rid="CR21">21</xref>&#8211;<xref ref-type="bibr" rid="CR27">27</xref>]. Understanding these behaviors in rural settings could inform future interventions to reduce fatal overdoses. Past research in mostly urban settings has highlighted a variety of strategies that people who use drugs employ to mitigate overdose risks. These include buying drugs from trusted sellers [<xref ref-type="bibr" rid="CR28">28</xref>]; sniffing, snorting, or smoking rather than injecting [<xref ref-type="bibr" rid="CR29">29</xref>]; using drugs in smaller increments; and testing the potency of their drugs by injecting a &#8220;test dose&#8221; [<xref ref-type="bibr" rid="CR30">30</xref>]. There are also tools available to reduce the risk of overdose and to reverse opioid-related overdoses. Fentanyl test strips can be used to test drugs prior to use [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>], and although they do not provide information about how much fentanyl is present, drug-using behaviors may be altered as a result [<xref ref-type="bibr" rid="CR33">33</xref>]. More advanced drug checking techniques, such as spectrometry, can identify contaminants in the drug supply, but these are rare in the U.S. and often cannot determine sample concentrations [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par9">In the event of an overdose, naloxone, an opioid antagonist, can be used to reverse it, although it is not always available and even when it is, barriers such as stigma and fear of arrest discourage carrying it [<xref ref-type="bibr" rid="CR35">35</xref>]. Most prior studies have focused on urban populations and those conducted in rural areas have had modest sample sizes. Given limited resources and barriers to harm reduction tools and strategies in rural communities, this study sought to explore a large, regionally diverse U.S. sample of rural people who use drugs and the strategies they employ to prevent fatal overdose.</p><sec id="Sec2"><title>Rurality in the United States</title><p id="Par10">People who use drugs in rural settings often have reduced access to resources compared to their urban counterparts increasing the risk for overdose fatality. For example, rural populations are more likely to be under- or uninsured and have difficulty accessing healthcare, due, in part, to transportation obstacles [<xref ref-type="bibr" rid="CR36">36</xref>&#8211;<xref ref-type="bibr" rid="CR40">40</xref>] and fewer physicians practicing in rural areas compared to urban areas [<xref ref-type="bibr" rid="CR40">40</xref>]. Rural communities also often lack providers of medications for opioid use disorder (MOUD) and harm reduction services including sterile syringe exchange and access to naloxone, both of which are associated with decreased overdose risk [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par11">Research has also identified structural and community factors specific to rural populations. For example, stigma can be high in rural settings for people who use drugs [<xref ref-type="bibr" rid="CR43">43</xref>&#8211;<xref ref-type="bibr" rid="CR47">47</xref>], and there may be fewer economic opportunities (Walzer, 2003) that, in turn, increase stress and other psychosocial issues associated with drug use [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Together, lack of access to services, stigma, and economic deprivation create unique overdose risk environments in rural settings [<xref ref-type="bibr" rid="CR50">50</xref>]. This investigation sought to explore ways in which rural people who use drugs employed harm reduction techniques to prevent fatal overdose.</p></sec><sec id="Sec3"><title>Harm reduction as a theoretical framework</title><p id="Par12">Harm reduction is a pragmatic and compassionate public health approach that focuses on minimizing the adverse health, social, and legal impacts associated with drug use, rather than solely aiming to eliminate drug use itself [<xref ref-type="bibr" rid="CR51">51</xref>]. Central to harm reduction theory is the acknowledgment of the complex and multifaceted nature of drug use, recognizing that it stems from a variety of factors including social, economic, and psychological influences. This approach acknowledges complexities and seeks to improve individual and community well-being by providing strategies and services that reduce risks. In this paper we use harm reduction as a theoretical basis for examining how people who use drugs mitigate the risks of fentanyl exposure and fatal overdose.</p><p id="Par13">Policy responses to drug use have historically been framed by the notion that it is an inherently negative activity best approached by promoting complete abstinence. Harm reduction as a policy for addressing infectious diseases associated with illicit drug use, emerged in the 1980&#8217;s primarily in the United Kingdom, Australia and Netherlands. This approach views drug use through a value-neutral lens and argues that minimizing drug use harms should be the primary aim of policy responses [<xref ref-type="bibr" rid="CR52">52</xref>&#8211;<xref ref-type="bibr" rid="CR55">55</xref>]. Harm reduction does not stigmatize individuals who use drugs, rather it advocates for policies and interventions aimed at reducing the harms, many of which (e.g., policies) are socially constructed [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>].</p><p id="Par14">Harm reduction interventions are grounded in evidence-based practices that have been shown to decrease the spread of infectious diseases, prevent overdose deaths, and engage people who use drugs in treatment and care without requiring abstinence. Some examples include syringe services programs (SSPs), drug testing services, and safe consumption sites (also termed overdose prevention centers). SSPs have been studied extensively and are associated with substantially reduced rates of HIV and HCV transmission as well as reduced rates of both fatal and non-fatal overdose [<xref ref-type="bibr" rid="CR56">56</xref>&#8211;<xref ref-type="bibr" rid="CR59">59</xref>]. Similarly drug testing and overdose prevention centers are associated with reduced fatal overdoses [<xref ref-type="bibr" rid="CR60">60</xref>&#8211;<xref ref-type="bibr" rid="CR63">63</xref>]. Harm reduction perspectives conceptualize the harms of substance use within their larger social context (i.e., criminalization of drug use and/or drug paraphernalia laws) rather than solely on the individual level [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR64">64</xref>&#8211;<xref ref-type="bibr" rid="CR66">66</xref>]. Structural factors are thought to constrain and stigmatize activities involved in drug use and harm reduction behaviors in ways that cause harm [<xref ref-type="bibr" rid="CR67">67</xref>].</p><p id="Par15">Given that many formal harm reduction interventions are inaccessible to people who use drugs, especially those in rural settings [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>], this study explores actions that people individually and collectively take to reduce the risk of fatal overdose. There are limited prior studies that highlight protective behaviors among people who use drugs. Past qualitative studies in the U.S. (mostly conducted in urban areas) have found that people alter their drug use by ingesting less or changing the route of administration to reduce the risk of fatal overdose [<xref ref-type="bibr" rid="CR30">30</xref>]. Other studies, one in Rhode Island study [<xref ref-type="bibr" rid="CR28">28</xref>] and one in rural Southern Illinois [<xref ref-type="bibr" rid="CR70">70</xref>] found an increased reliance on drug sellers to inform them about contaminants in the drug supply and felt more secure purchasing from people they trusted. Studies have also explored naloxone access and use [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR71">71</xref>], noting the concern that naloxone is often not available in rural areas [<xref ref-type="bibr" rid="CR72">72</xref>]. Considering the ongoing elevated risks, it is critical to document all of the strategies&#8212;both evidence-based and otherwise &#8211; utilized by people who use drugs to prevent overdose in rural settings.</p></sec></sec><sec id="Sec4"><title>Methods</title><sec id="Sec5"><title>Study background</title><p id="Par16">This analysis used qualitative data from the Rural Opioid Initiative (ROI) for this study. The ROI was developed in 2015 when the US was experiencing high levels of opioid use and injection drug use that disproportionately impacted rural communities [<xref ref-type="bibr" rid="CR73">73</xref>]. Over the course of the study, recognition of the increasingly significant role of polysubstance related drug overdose deaths has increased and recognition that the US is currently passing through a wave of the overdose that is characterized by mortality related to polysubstance use. The ROI was funded by the National Institute on Drug Abuse (NIDA), in partnership with the Appalachian Regional Commission (ARC), the Centers for Disease Control and Prevention (CDC) and the Substance Abuse and Mental Health Services Administration (SAMHSA), and consisted of eight research sites located in rural areas. All sites aimed to understand drug use in their local area and to develop comprehensive approaches to prevent and treat harmful outcomes related to drug use. NIDA also funded the Rural Comorbidity and HIV Consequences of Opioid Use Research and Treatment Initiative Data Coordinating Center (DCC) that compiled data from all sites, including qualitative data.</p><p id="Par17">Rurality was defined based on the US Health Resources and Services Administration (HRSA) &#8220;Am I Rural&#8221; website. The website uses definitions of rurality from several US federal programs, including the US Census Bureau, the Office of Management and Budget (OMB), and the Economic Research Service of the U.S. Department of Agriculture (USDA-ERS). The federal ROI funding agencies used this website to inform research study selection and study sites confirmed rurality and other indicators of vulnerability during the application process.</p><p id="Par18">The eight research sites spanned 65 counties in 10 states (Illinois, Kentucky, Massachusetts, New Hampshire, North Carolina, Ohio, Oregon, Vermont, West Virginia, and Wisconsin) with high rates of substance use, overdose, and infectious disease rates [<xref ref-type="bibr" rid="CR73">73</xref>]. Given the large geographic span, there was diversity not only in location but also in participants and local drug use practiced and norms. For example, New England (NE) (referred to as the NE study site throughout this paper) included contiguous communities located along the Connecticut River Valley in western Massachusetts, Eastern Vermont, and western New Hampshire. Some sites were located in Appalachia, a cultural and geographical region that spans 13 states from New York to Mississippi. These included Eastern Kentucky, western North Carolina, West Virginia, and Southeastern Ohio. All rural communities included in the study have experienced increased vulnerability to fatal overdose, HCV transmission and concern for HIV transmission due to high rates of injection drug use and limited access to healthcare [<xref ref-type="bibr" rid="CR74">74</xref>&#8211;<xref ref-type="bibr" rid="CR76">76</xref>].</p><p id="Par19">The first phase of the ROI included epidemiologic and policy scans, and the collection of harmonized qualitative and quantitative data. The second phase focused on site-specific and data-informed interventions, which differed by site depending on the needs identified in the initial phase. This paper uses qualitative data from the first phase to describe harm reduction techniques that participants employed to reduce their risk of experiencing fatal overdoses.</p><p id="Par20">Rurality was defined using the US Health Resources and Services Administration (HRSA) &#8220;Am I Rural&#8221; website. The website uses definitions of rurality from a number of US federal programs, including the US Census Bureau, the Office of Management and Budget (OMB), and the Economic Research Service of the U.S. Department of Agriculture (USDA-ERS). ROI funding agencies used this website to inform site selection and study sites confirmed rurality and other indicators of vulnerability during the application process.</p><p id="Par21">The eight research sites spanned 65 counties in 10 states (Illinois, Kentucky, Massachusetts, New Hampshire, North Carolina, Ohio, Oregon, Vermont, West Virginia, and Wisconsin) with high substance use, overdose, and infectious disease rates (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ruralopioidinitiative.org/studies.html">https://ruralopioidinitiative.org/studies.html</ext-link> for more information about each site) [<xref ref-type="bibr" rid="CR73">73</xref>]. Given the large span of rural counties, there was diversity in location, participants, and drug use norms. New England (NE) (referred to as the NE study site throughout this paper) included contiguous communities located along the Connecticut River Valley in western Massachusetts, Eastern Vermont, and western New Hampshire. Some sites were located in Appalachia, a cultural and geographical region that spans 13 states from New York to Mississippi. These included Eastern Kentucky, western North Carolina, west Virginia, and Southeastern Ohio. Wisconsin and Illinois sites were located in rural Midwestern US counties. Oregon included coastal and land-locked communities in large, thinly populated counties. All rural communities included in the study have experienced increased vulnerability to fatal overdose, HCV transmission and concern for HIV transmission due to high rates of injection drug use and limited access to healthcare [<xref ref-type="bibr" rid="CR74">74</xref>&#8211;<xref ref-type="bibr" rid="CR76">76</xref>].</p><p id="Par22">The first phase of the ROI involved epidemiologic and policy scans, and the collection of harmonized qualitative and quantitative data. The second phase of the ROI focused on data-informed and site-specific interventions, which differed by sight, depending on the identified needs in the first phase. This paper uses qualitative data from the first phase to describe qualitative findings focused on harm reduction techniques rural participants employed to reduce their risks of experiencing fatal overdoses.</p></sec><sec id="Sec6"><title>Semi-structured qualitative interview guide</title><p id="Par23">A cross-site ROI working group with expertise in qualitative methods developed and harmonized the interview guide used across sites. Interview domains included: background (e.g., specifics to the region such as questions tailored to the local drug market, social networks, family); past and current drug use; drug use behaviors; overdose experiences; sexual behaviors; interactions with law enforcement; and experiences with healthcare and other service providers. Specific questions about fentanyl were indicated as probes. People who indicated that they injected drugs could be asked: &#8220;<italic toggle="yes">Have you ever used any drugs containing fentanyl?&#8221;, &#8220;Did you realize before or after you took the drug that it contained fentanyl?&#8221;, and &#8220;Were you seeking a drug that contained fentanyl, or were you unaware?&#8221;</italic> Outside of these questions, fentanyl discussions emerged from participant narratives, often when they were describing overdose experiences. Although the fentanyl probes were listed under the question about injection drug use, the interviews were semi-structured and allowed for the interviewer to probe at any time during interviews. See Online Appendix A for the interview guide.</p><p id="Par24">There were no harmonized questions about fentanyl test strips, which were not in wide use when the study was designed; thus, this information emerged through the semi-structured methodology, which allowed participants to talk freely and for interviewers to probe. Similarly, there were no harmonized questions about naloxone; however, questions in the interview guides were used as probes to the following question: <italic toggle="yes">&#8220;Now I&#8217;ll ask about your experience with overdosing, which includes if you passed out, turned blue, or stopped breathing from using drugs. Have you ever overdosed?&#8221;</italic> If participants answered yes to overdosing, they were asked, <italic toggle="yes">&#8220;Tell me about the most recent time that you overdosed.&#8221;</italic> Probes to this question, which could have been asked in the interviews, included: <italic toggle="yes">&#8220;Was Narcan/naloxone used? If yes, who administered the Narcan/naloxone first?&#8221;</italic> Similarly, participants were asked about witnessing someone else overdosing. If participants responded yes, the same probes were used. to witnessing an overdose, they could receive the following probes: &#8220;<italic toggle="yes">Was Narcan/naloxone used?&#8221;</italic> Participants who responded yes could also be asked:<italic toggle="yes">&#8220;Do you currently have Narcan/naloxone with you or at home?&#8221;</italic> and<italic toggle="yes"> &#8220;If you wanted to get Narcan/naloxone, do you know how to get it?&#8221;.</italic></p><p id="Par25">Each study received approval from the local institutional review board and participant privacy was protected by a federal Certificate of Confidentiality.</p></sec><sec id="Sec7"><title>Participant recruitment and data collection</title><p id="Par26">Between 2018 and early 2020, people who use drugs were recruited to participate in a 60&#8211;90-min semi-structured qualitative interview. Eligibility criteria and recruitment methods differed slightly by site (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>); however, all participants resided in the study area and disclosed recent opioid use or injection drug use. Participation of individuals who may not have used opioids but did inject drugs was more common in areas where methamphetamine use was prominent. All sites recruited participants from community-based programs, and in some cases used novel community-based recruitment methods, such as community cookouts [<xref ref-type="bibr" rid="CR77">77</xref>]. Study staff trained in qualitative methods conducted interviews, which were digitally recorded and transcribed. All participants gave written informed consent to participate and were compensated between $25&#8211;50 depending on local site protocol.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Eligibility criteria and qualitative recruitment method, by site</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Site</th><th align="left" colspan="1" rowspan="1">Eligibility criteria</th><th align="left" colspan="1" rowspan="1">Qualitative recruitment method</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">IL</td><td align="left" colspan="1" rowspan="1">Age&#8201;&#8805;&#8201;15&#160;years</td><td align="left" colspan="1" rowspan="1">Participation in the study site questionnaire/UG3/ ROI survey (i.e., participation in the quantitative study)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Current resident in study area</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">English-speaking</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Opioid use or methamphetamine injection in past 30&#160;days</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Accepts referral to harm reduction services</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">KY</td><td align="left" colspan="1" rowspan="1">Age&#8201;&#8805;&#8201;18&#160;years</td><td align="left" colspan="1" rowspan="1">Participation in the study site questionnaire/UG3/ ROI survey (i.e., participation in the quantitative study)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Current resident in study area</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">English-speaking</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Injected drugs or used opioids to get high within past 30&#160;days</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">NC</td><td align="left" colspan="1" rowspan="1">Age&#8201;&#8805;&#8201;18&#160;years</td><td align="left" colspan="1" rowspan="1">Participation in the study site questionnaire/UG3/ ROI survey (i.e., participation in the quantitative study)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Current resident in study area and intends to stay 12&#160;months</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">English-speaking</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Opioid or methamphetamine injection in past 30&#160;days</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Verification by stigmata or appropriate description of injection practices</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Indication in questionnaire of having injected painkillers or heroin</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">NE</td><td align="left" colspan="1" rowspan="1">Age&#8201;&#8805;&#8201;18&#160;years</td><td align="left" colspan="1" rowspan="1">Convenience sample of in-depth interview participants through street outreach, venue-based recruitment, and respondent driven sampling from the UG3/ROI survey (i.e., participation in the quantitative study)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Spent most of the last 30&#160;days in the study area</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Used opioids to get high or injected any drug in the last 30&#160;days</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Able to provide informed consent</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">English-speaking</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">OH</td><td align="left" colspan="1" rowspan="1">Age&#8201;&#8805;&#8201;18</td><td align="left" colspan="1" rowspan="1">Community partners and key informants</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Current resident in study area</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Used heroin or prescription opioids or injected any type of drug to get high in the past 30&#160;days</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">OR</td><td align="left" colspan="1" rowspan="1">Age&#8201;&#8805;&#8201;18</td><td align="left" colspan="1" rowspan="1">Advertisement in community-based and service locations; direct recruitment by service provider and outreach staff</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Current resident in study area</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">English-speaking</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Injected any drug or used opioids to get high in the past 30&#160;days</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">WI</td><td align="left" colspan="1" rowspan="1">Age&#8201;&#8805;&#8201;15</td><td align="left" colspan="1" rowspan="1">Participation in the study site questionnaire/UG3/ ROI survey (i.e., participation in the quantitative study)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Current resident in study area</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Injected any opioid drug in the past 30&#160;days</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">WV</td><td align="left" colspan="1" rowspan="1">Age&#8201;&#8805;&#8201;18</td><td align="left" colspan="1" rowspan="1">Direct recruitment by outreach staff and service providers of dynamic individuals&#8217; well-known communities of people who use drugs</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Current resident in study area</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Injection drug us in past 30&#160;days</td><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>United States abbreviations are as follows: Illinois (IL), Kentucky (KY), North Carolina (NC), New England (NE), Ohio (OH), Oregon (OR), Wisconsin (WI), West Virginia (WV)</p></table-wrap-foot></table-wrap></p><p id="Par27">Recruitment and data collection also were context specific. For example, some sites' local drug markets were dominated by methamphetamines, and therefore, to understand the specific contexts and risks for overdose, those sites proactively recruited people who used methamphetamines. Although each ROI study site had to adapt to the specific needs of their community, the study sites remained in contact and when possible aligned methods, harmonized the qualitative interview guide, and worked collaboratively across sites throughout data analyses. More information about the ROI has been published elsewhere [<xref ref-type="bibr" rid="CR73">73</xref>].</p></sec><sec id="Sec8"><title>Data analysis</title><p id="Par28">Researchers with experience in anthropology, epidemiology, public health, addiction medicine, harm reduction, and social services conducted in-person interviews at each site. Interviews were audio recorded for all sites and professionally transcribed. All transcripts were de-identified and assigned a unique identification number, then uploaded to a qualitative software program (Dedoose, Los Angeles, CA, v. 09.0.62) for data management, coding, and analyses. Researchers with expertise in qualitative methods from the ROI Data Coordinating Center (DCC) conducted preliminary coding to categorize data by interview topic areas and lines of inquiry. This preliminary coding used a deductive coding technique that aligned codes to the interview questions. The DCC created a code book that included all ROI site data.</p><p id="Par29">We then comprised the writing team with representatives from all ROI sites to analyze data compiled by the DCC. The interdisciplinary writing team had expertise in epidemiology (TS, AR, MF), anthropology (RF), sociology (SW, DF, RB, LO) public health (WZ, TS, SW, RB, AS, VG, LO, MP, DS, JF, DS, GS) infectious disease (MP, DS, JF), and drug use (WZ, TS, SW, RB, AS, VG, LO, MP, DS, JF, DS, GS). We explored all codes that were related to overdose and fentanyl and used an inductive thematic analysis approach to identify emergent themes and create new codes accordingly. This is a data-driven coding method that has similarities to grounded theory [<xref ref-type="bibr" rid="CR78">78</xref>] in that the data dictates the codes; however, it is done after data collection [<xref ref-type="bibr" rid="CR79">79</xref>]. During monthly meetings team members presented the themes that emerged from the data they had reviewed. To ensure intercoder reliability, three people were assigned to evaluate initial coding. All coding decisions were discussed in our writing team meetings until a consensus was reached.</p><p id="Par30">During this inductive coding process, the study team identified harm reduction techniques that study participants referenced in their narratives about fentanyl. We consolidated the harm reduction themes as needed and created appropriate sub-codes. Since the writing team only explored data that had been deductively coded in the initial code book, developed by the DCC, which focused on overdose and fentanyl, we queried the entire dataset for specific words that emerged from our inductive coding that could potentially have been missed in the DCC deductive coding scheme. After including additional quotes, we finalized the codebook, reviewing the codes to identify redundancies and potential gaps and refining code definitions to ensure accuracy and clarity.</p></sec></sec><sec id="Sec9"><title>Results</title><p id="Par31">A total of 349 qualitative interviews were included in this analysis. Slightly over half of participants were male, with ages ranging from 20 to 63&#160;years old, and most participants reported being white. Table <xref rid="Tab2" ref-type="table">2</xref> provides demographic information by site.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Demographic characteristics of 349 people who used drugs in 8 rural US studies, 2018&#8211;2020</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Total</th><th align="left" colspan="1" rowspan="1">Illinois</th><th align="left" colspan="1" rowspan="1">Kentucky</th><th align="left" colspan="1" rowspan="1">North Carolina</th><th align="left" colspan="1" rowspan="1">New England</th><th align="left" colspan="1" rowspan="1">Ohio</th><th align="left" colspan="1" rowspan="1">Oregon</th><th align="left" colspan="1" rowspan="1">Wisconsin</th><th align="left" colspan="1" rowspan="1">West Virginia<sup>f</sup></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Interviewees (data sent by studies used)</td><td align="left" colspan="1" rowspan="1">349 (100%)</td><td align="left" colspan="1" rowspan="1">22 (6%)</td><td align="left" colspan="1" rowspan="1">57 (16%)</td><td align="left" colspan="1" rowspan="1">65 (19%)</td><td align="left" colspan="1" rowspan="1">22 (6%)</td><td align="left" colspan="1" rowspan="1">26 (7%)</td><td align="left" colspan="1" rowspan="1">52 (15%)</td><td align="left" colspan="1" rowspan="1">60 (17%)</td><td align="left" colspan="1" rowspan="1">45 (13%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Male<sup>a</sup></td><td align="left" colspan="1" rowspan="1">194 (64%)</td><td align="left" colspan="1" rowspan="1">14 (64%)</td><td align="left" colspan="1" rowspan="1">35 (61%)</td><td align="left" colspan="1" rowspan="1">34 (52%)</td><td align="left" colspan="1" rowspan="1">10 (45%)</td><td align="left" colspan="1" rowspan="1">15 (58%)</td><td align="left" colspan="1" rowspan="1">28 (54%)</td><td align="left" colspan="1" rowspan="1">33 (55%)</td><td align="left" colspan="1" rowspan="1">25 (56%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Average age</td><td align="left" colspan="1" rowspan="1">36</td><td align="left" colspan="1" rowspan="1">37</td><td align="left" colspan="1" rowspan="1">35</td><td align="left" colspan="1" rowspan="1">36</td><td align="left" colspan="1" rowspan="1">33</td><td align="left" colspan="1" rowspan="1">37</td><td align="left" colspan="1" rowspan="1">39</td><td align="left" colspan="1" rowspan="1">35</td><td align="left" colspan="1" rowspan="1">38</td></tr><tr><td align="left" colspan="1" rowspan="1">Race</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">White</td><td align="left" colspan="1" rowspan="1">213 (61%)</td><td align="left" colspan="1" rowspan="1">20 (91%)</td><td align="left" colspan="1" rowspan="1">56 (98%)</td><td align="left" colspan="1" rowspan="1">15 (23%)</td><td align="left" colspan="1" rowspan="1">15 (68%)</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">not asked</italic></td><td align="left" colspan="1" rowspan="1">49 (94%)</td><td align="left" colspan="1" rowspan="1">58 (97%)</td><td align="left" colspan="1" rowspan="1">(0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Black</td><td align="left" colspan="1" rowspan="1">2 (1%)</td><td align="left" colspan="1" rowspan="1">2 (9%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Native American</td><td align="left" colspan="1" rowspan="1">8 (2%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">5 (8%)</td><td align="left" colspan="1" rowspan="1">1 (5%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1 (2%)</td><td align="left" colspan="1" rowspan="1">1 (2%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mixed race</td><td align="left" colspan="1" rowspan="1">5 (1%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">2 (3%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">2 (4%)</td><td align="left" colspan="1" rowspan="1">1 (2%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Other</td><td align="left" colspan="1" rowspan="1">1 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">1 (2%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Not given/Not asked<sup>b</sup></td><td align="left" colspan="1" rowspan="1">120 (34%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">43 (66%)</td><td align="left" colspan="1" rowspan="1">6 (27%)</td><td align="left" colspan="1" rowspan="1">26<sup>2</sup> (100%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">45 (100%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Interviewees (coded interview data used)</td><td align="left" colspan="1" rowspan="1">349 (100%)</td><td align="left" colspan="1" rowspan="1">22 (6%)</td><td align="left" colspan="1" rowspan="1">57 (16%)</td><td align="left" colspan="1" rowspan="1">65 (19%)</td><td align="left" colspan="1" rowspan="1">22 (6%)</td><td align="left" colspan="1" rowspan="1">26 (7%)</td><td align="left" colspan="1" rowspan="1">52 (15%)</td><td align="left" colspan="1" rowspan="1">60 (17%)</td><td align="left" colspan="1" rowspan="1">45 (13%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Substance use</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Ever IDU</td><td align="left" colspan="1" rowspan="1">331 (95%)</td><td align="left" colspan="1" rowspan="1">20 (91%)</td><td align="left" colspan="1" rowspan="1">57 (100%)</td><td align="left" colspan="1" rowspan="1">65 (100%)</td><td align="left" colspan="1" rowspan="1">21 (95%)</td><td align="left" colspan="1" rowspan="1">17 (65%)</td><td align="left" colspan="1" rowspan="1">52 (100%)</td><td align="left" colspan="1" rowspan="1">56 (93%)</td><td align="left" colspan="1" rowspan="1">43 (96%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Current IDU</td><td align="left" colspan="1" rowspan="1">318 (91%)</td><td align="left" colspan="1" rowspan="1">19 (86%)</td><td align="left" colspan="1" rowspan="1">57 (100%)</td><td align="left" colspan="1" rowspan="1">65 (100%)</td><td align="left" colspan="1" rowspan="1">18 (82%)</td><td align="left" colspan="1" rowspan="1">15 (58%)</td><td align="left" colspan="1" rowspan="1">50 (96%)</td><td align="left" colspan="1" rowspan="1">55 (92%)</td><td align="left" colspan="1" rowspan="1">39 (87%)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Heroin</italic></td><td align="left" colspan="1" rowspan="1">214 (61%)</td><td align="left" colspan="1" rowspan="1">8 (36%)</td><td align="left" colspan="1" rowspan="1">30 (53%)</td><td align="left" colspan="1" rowspan="1">51 (78%)</td><td align="left" colspan="1" rowspan="1">18 (82%)</td><td align="left" colspan="1" rowspan="1">13 (50%)</td><td align="left" colspan="1" rowspan="1">41 (79%)</td><td align="left" colspan="1" rowspan="1">34 (57%)</td><td align="left" colspan="1" rowspan="1">19 (42%)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Fentanyl</italic></td><td align="left" colspan="1" rowspan="1">78 (22%)</td><td align="left" colspan="1" rowspan="1">1 (5%)</td><td align="left" colspan="1" rowspan="1">17 (30%)</td><td align="left" colspan="1" rowspan="1">26 (40%)</td><td align="left" colspan="1" rowspan="1">14 (64%)</td><td align="left" colspan="1" rowspan="1">3 (12%)</td><td align="left" colspan="1" rowspan="1">6 (12%)</td><td align="left" colspan="1" rowspan="1">6 (10%)</td><td align="left" colspan="1" rowspan="1">5 (11%)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Methamphetamine</italic></td><td align="left" colspan="1" rowspan="1">225 (64%)</td><td align="left" colspan="1" rowspan="1">14 (64%)</td><td align="left" colspan="1" rowspan="1">37 (65%)</td><td align="left" colspan="1" rowspan="1">61 (94%)</td><td align="left" colspan="1" rowspan="1">4 (18%)</td><td align="left" colspan="1" rowspan="1">6 (23%)</td><td align="left" colspan="1" rowspan="1">47 (90%)</td><td align="left" colspan="1" rowspan="1">41 (68%)</td><td align="left" colspan="1" rowspan="1">15 (33%)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Other</italic></td><td align="left" colspan="1" rowspan="1">226 (65%)</td><td align="left" colspan="1" rowspan="1">4 (18%)</td><td align="left" colspan="1" rowspan="1">54 (95%)</td><td align="left" colspan="1" rowspan="1">61 (94%)</td><td align="left" colspan="1" rowspan="1">15 (68%)</td><td align="left" colspan="1" rowspan="1">10 (38%)</td><td align="left" colspan="1" rowspan="1">21 (40%)</td><td align="left" colspan="1" rowspan="1">28 (47%)</td><td align="left" colspan="1" rowspan="1">33 (73%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Surveyed Interviewees<sup>c</sup> (survey data used)</td><td align="left" colspan="1" rowspan="1">144 (100%)</td><td align="left" colspan="1" rowspan="1">22 (15%)</td><td align="left" colspan="1" rowspan="1">23 (16%)</td><td align="left" colspan="1" rowspan="1">23 (16%)</td><td align="left" colspan="1" rowspan="1">16 (11%)</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">60 (42%)</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">Substance use</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Current (Past 30 days)</td><td align="left" colspan="1" rowspan="1">143 (100%)</td><td align="left" colspan="1" rowspan="1">22 (100%)</td><td align="left" colspan="1" rowspan="1">23 (100%)</td><td align="left" colspan="1" rowspan="1">23 (100%)</td><td align="left" colspan="1" rowspan="1">16 (100%)</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">59 (98%)</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">Recruited by</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Service or program staff</td><td align="left" colspan="1" rowspan="1">6 (4%)</td><td align="left" colspan="1" rowspan="1">2 (9%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">4 (17%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">Other</td><td align="left" colspan="1" rowspan="1">83 (58%)</td><td align="left" colspan="1" rowspan="1">11 (50%)</td><td align="left" colspan="1" rowspan="1">14 (61%)</td><td align="left" colspan="1" rowspan="1">9 (39%)</td><td align="left" colspan="1" rowspan="1">14 (88%)</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">35 (58%)</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">Not indicated</td><td align="left" colspan="1" rowspan="1">55 (38%)</td><td align="left" colspan="1" rowspan="1">9 (41%)</td><td align="left" colspan="1" rowspan="1">9 (39%)</td><td align="left" colspan="1" rowspan="1">10 (43%)</td><td align="left" colspan="1" rowspan="1">2 (13%)</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">25 (42%)</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">Interviewees (data sent by studies used)</td><td align="left" colspan="1" rowspan="1">304 (100%)</td><td align="left" colspan="1" rowspan="1">22 (7%)</td><td align="left" colspan="1" rowspan="1">57 (19%)</td><td align="left" colspan="1" rowspan="1">65 (21%)</td><td align="left" colspan="1" rowspan="1">22 (7%)</td><td align="left" colspan="1" rowspan="1">26 (9%)</td><td align="left" colspan="1" rowspan="1">52 (17%)</td><td align="left" colspan="1" rowspan="1">60 (20%)</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">Education</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;High school</td><td align="left" colspan="1" rowspan="1">56 (18%)</td><td align="left" colspan="1" rowspan="1">1 (5%)</td><td align="left" colspan="1" rowspan="1">21 (37%)</td><td align="left" colspan="1" rowspan="1">13 (20%)</td><td align="left" colspan="1" rowspan="1">3 (14%)</td><td align="left" colspan="1" rowspan="1">7 (27%)</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">not asked</italic></td><td align="left" colspan="1" rowspan="1">11 (18%)</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">not asked</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">H.S. or GED</td><td align="left" colspan="1" rowspan="1">97 (32%)</td><td align="left" colspan="1" rowspan="1">11 (50%)</td><td align="left" colspan="1" rowspan="1">22 (39%)</td><td align="left" colspan="1" rowspan="1">21 (32%)</td><td align="left" colspan="1" rowspan="1">9 (41%)</td><td align="left" colspan="1" rowspan="1">11 (42%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">23 (38%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Some college</td><td align="left" colspan="1" rowspan="1">61 (20%)</td><td align="left" colspan="1" rowspan="1">7 (32%)</td><td align="left" colspan="1" rowspan="1">6 (11%)</td><td align="left" colspan="1" rowspan="1">20 (31%)</td><td align="left" colspan="1" rowspan="1">3 (14%)</td><td align="left" colspan="1" rowspan="1">6 (23%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">19 (32%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Assoc/trade deg</td><td align="left" colspan="1" rowspan="1">16 (5%)</td><td align="left" colspan="1" rowspan="1">3 (14%)</td><td align="left" colspan="1" rowspan="1">8 (14%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">1 (5%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">4 (7%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8201;&gt;&#8201;&#8201;=&#8201;B.A</td><td align="left" colspan="1" rowspan="1">12 (4%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">8 (12%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">1 (4%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">3 (5%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Not answered<sup>d</sup></td><td align="left" colspan="1" rowspan="1">62 (20%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">3 (5%)</td><td align="left" colspan="1" rowspan="1">6 (27%)</td><td align="left" colspan="1" rowspan="1">1 (4%)</td><td align="left" colspan="1" rowspan="1">52<sup>d</sup> (100%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Income Source</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Full-time work (40 h/wk)</td><td align="left" colspan="1" rowspan="1">44 (14%)</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">not asked</italic></td><td align="left" colspan="1" rowspan="1">6 (11%)</td><td align="left" colspan="1" rowspan="1">13 (20%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">10 (38%)</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">not asked</italic></td><td align="left" colspan="1" rowspan="1">15 (25%)</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">not asked</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">Part-time work</td><td align="left" colspan="1" rowspan="1">26 (9%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">6 (11%)</td><td align="left" colspan="1" rowspan="1">7 (11%)</td><td align="left" colspan="1" rowspan="1">2 (9%)</td><td align="left" colspan="1" rowspan="1">1 (4%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">10 (17%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Retirement check</td><td align="left" colspan="1" rowspan="1">2 (1%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">2 (4%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Public assistance check &#8211; like TANF, AFDC etc</td><td align="left" colspan="1" rowspan="1">29 (10%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">29 (51%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Disability check, like SSI, military or other</td><td align="left" colspan="1" rowspan="1">19 (6%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">10 (15%)</td><td align="left" colspan="1" rowspan="1">4 (18%)</td><td align="left" colspan="1" rowspan="1">1 (4%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">4 (7%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Selling drugs</td><td align="left" colspan="1" rowspan="1">4 (1%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">1 (5%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">3 (5%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Selling sex</td><td align="left" colspan="1" rowspan="1">1 (0%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1 (2%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Theft, shoplifting etc</td><td align="left" colspan="1" rowspan="1">3 (1%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">1 (5%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">2 (3%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Someone supports me</td><td align="left" colspan="1" rowspan="1">15 (5%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">2 (9%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">13 (22%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Other</td><td align="left" colspan="1" rowspan="1">12 (4%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">6 (27%)</td><td align="left" colspan="1" rowspan="1">1 (4%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">5 (8%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Unemployed</td><td align="left" colspan="1" rowspan="1">59 (19%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">13 (23%)</td><td align="left" colspan="1" rowspan="1">34 (52%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">12 (46%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Missing<sup>e</sup></td><td align="left" colspan="1" rowspan="1">90 (30%)</td><td align="left" colspan="1" rowspan="1">22<sup>e</sup> (100%)</td><td align="left" colspan="1" rowspan="1">1 (2%)</td><td align="left" colspan="1" rowspan="1">1 (2%)</td><td align="left" colspan="1" rowspan="1">6 (27%)</td><td align="left" colspan="1" rowspan="1">1 (4%)</td><td align="left" colspan="1" rowspan="1">52<sup>e</sup> (100%)</td><td align="left" colspan="1" rowspan="1">7 (12%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>One interviewee from OR identified as &#8220;Neither&#8221;male of female</p><p><sup>b</sup>Some NC and NE interviewees did not give their race/ethnicity. OH did not ask interviewees their race/ethnicity</p><p><sup>c</sup>Some, but not all, participants completed a quantitative survey before their interview</p><p><sup>d</sup>OR did not ask interviewees about education</p><p><sup>e</sup>IL and OR did not ask interviewees about income source. WI had 4 &#8220;Refuse to answer and 3 &#8220;Don&#8217;t know&#8221; responses. KY, NC, NE and OH had interviewees who did not answer the question</p><p><sup>f</sup>WV did not ask questions about race, ethnicity, or education</p><p><sup>g</sup>Ethnicity data (e.g., Hispanic, non-Hispanic) was not collected</p><p><sup>h</sup>United States abbreviations are as follows: Illinois (IL), Kentucky (KY), North Carolina (NC), New England (NE, including Massachusetts, New Hampshire, and Vermont), Ohio (OH), Oregon (OR), Wisconsin (WI), West Virginia (WV)</p></table-wrap-foot></table-wrap></p><sec id="Sec10"><title>Fentanyl awareness</title><p id="Par32">Participants were aware of fentanyl contamination in their drug supply and noted that its presence was common whether they used opioids or stimulants. Participants explained: <italic toggle="yes">&#8220;Every other bag of heroin you get, or every other fake 30 you get, is cut with fentanyl&#8221;</italic> (West Virginia, male, age 20). Another participant said, &#8220;<italic toggle="yes">You gotta watch &#8216;cus some of the uh, the ice [methamphetamine] you get is cut with fentanyl and it&#8217;ll kill you&#8221;</italic> (Ohio, male, age 43).</p><p id="Par33">Despite the awareness that the drug supply likely contained fentanyl, most participants expressed some uncertainty regarding their own unintentional use. Participants described overdosing and shared that they suspected fentanyl was in the drugs they used because the effect was stronger than normal. Participants said things like, <italic toggle="yes">&#8220;I think I did fentanyl. Somebody told me it was China White [heroin], but I&#8217;m pretty sure it was fentanyl&#8221;</italic> (Oregon, male, age 25). When describing his most recent overdose one participant said,<disp-quote><p id="Par34">&#8220;It was either China or fentanyl. I was thinking it was fentanyl because it was so strong. Just a little bitty speck would put you in the floor almost. And I had probably done close to a tenth of a gram and mixed with a little meth. And I guess I fell out on the side of the wall into the toilet, against the wall. So, I'm leaned over against the wall, and I was passed out there. And they found me, and they woke me up, and my old lady tripped out on me, and she left&#8221; (Kentucky, male, age 31).</p></disp-quote></p><p id="Par35">Participants who use stimulants were also concerned about fentanyl adulteration in their drug supply. When discussing her methamphetamine use, one participant said,<disp-quote><p id="Par36">&#8220;There&#8217;s been a couple times where like me and whoever I&#8217;d be around- were like well, that must&#8217;ve been mixed with fentanyl because we did it and we would just go right to sleep, just nod off, and I felt like I was on heroin for a couple of times, and it was like weird&#8221; (Wisconsin, female, age 34).</p></disp-quote></p><p id="Par37">Experiences such as this led to concerns about the quality of drugs available, especially methamphetamine, because it seemed that fentanyl contamination had occurred more recently than in the heroin supply, and therefore was less expected.<disp-quote><p id="Par38">&#8220;My thought about fentanyl in general is it should not [be] able to be around, and I don&#8217;t know how they&#8217;re doing it but that&#8217;s why everybody&#8217;s getting so fucked up. You know you go and shoot meth and you&#8217;re not shooting just meth, it&#8217;s fentanyl, and it&#8217;s fucking people up&#8221; (Wisconsin, female, age 34).</p></disp-quote></p><p id="Par39">One man confirmed these suspicions through a positive drug screen: <italic toggle="yes">&#8220;I do the meth, the crystal, or the ice what they call it now. And even at that, that stuff is laced with all kinds of stuff. When I was at the Suboxone clinic they pulled blood, and they said I had fentanyl in me. And I hadn't done fentanyl in years, and it had to have come from the ice&#8221;</italic> (Kentucky, male, age 61).</p><p id="Par40">Despite regional trends in drug use, we did not see regional differences in fentanyl awareness. This is likely because participants, regardless of location, reported the perception that their drug supply was contaminated with fentanyl. Given the absence of a regulated drug supply and the ability to check drugs prior to use, participants developed several strategies to avoid overdoses associated with fentanyl. Most used multiple strategies at once to ensure success and avoid fatal overdose. Sometimes decisions were affected by whether participants were using heroin or methamphetamine, with many participants expressing greater concerns over adulteration when using heroin.</p></sec><sec id="Sec11"><title>Harm reduction strategies</title><sec id="Sec12"><title>Avoiding heroin</title><p id="Par41">Participants described using a variety of strategies to avoid unknowingly ingesting fentanyl; in particular, avoiding heroin was one theme that emerged. &#8220;<italic toggle="yes">I said &#8220;No more heroin. I ain&#8217;t using any more heroin. I don&#8217;t want to lose my life&#8230;Pain pills maybe, but no more heroin and no fentanyl, either</italic>&#8221; (Oregon, female, age 60). Other people talked about experiences with people close to them overdosing on heroin with fentanyl, which prompted their concerns and decision to avoid heroin:<disp-quote><p id="Par42">&#8220;I&#8217;ve had friends overdose on heroin, and I&#8217;ve had a couple die. That is what probably deterred me from ever using heroin. You know, like, you have some of the fentanyl, and what they put in it for cut, and you see it on TV and all the overdose, the deaths, and they talk about it continuously&#8221; (Wisconsin, male, age 47).</p></disp-quote></p><p id="Par43">A woman in Oregon said:<disp-quote><p id="Par44">&#8220;See, the heroin was getting cut with fentanyl for a while there in [location redacted]. I&#8217;m pretty sure I tried it, but I&#8217;ve seen my really good friend, and he almost died. Another friend of mine did die and they had to bring her back, and then my baby cousin died. So, I was not touching it. I&#8217;m not touching it definitely with a needle&#8221; (Oregon, female, age 39).</p></disp-quote></p><p id="Par45">The above participant says she will not use heroin, but at the end of her sentence says &#8220;definitely not with a needle&#8221; suggesting there may be a time she will use heroin, but she will exercise caution and change the way she uses it to protect herself.</p></sec><sec id="Sec13"><title>Buying from trusted people who sell drugs</title><p id="Par46">Since there was a palpable awareness and concern about potential fentanyl contamination in all drugs including stimulants, participants employed additional harm reduction measures. One tactic used was buying drugs from a trusted person. This is because <italic toggle="yes">&#8220;There&#8217;s some dealers that you trust more than others&#8221;</italic> (New England, male, age 39). Other participants described:<disp-quote><p id="Par47">&#8220;I absolutely will not buy from somebody that is a stranger ... because strangers don&#8217;t care. Um, I got to know who they are, and they have to know who I am, and have some degree of you know, respect between us before I&#8217;ll buy anything&#8221; (Ohio, female, age 32).</p></disp-quote></p><p id="Par48">Many participants described their relationships with the people from whom they purchased drugs as being built on trust and friendship. There was genuine care for each other and the people who sold drugs would look out for their customers: &#8220;<italic toggle="yes">My guy, specifically, he&#8217;s like &#8220;I don&#8217;t think I&#8217;m gonna sell it to you, man, because I don&#8217;t want you dying on me. And he actually did have concern for me, you know, he was still selling me heroin but he didn&#8217;t want me to die.&#8221;</italic> (Wisconsin, male, age 29). Stated another person:<disp-quote><p id="Par49">&#8220;First time I did fentanyl-based heroin, which is more fentanyl than heroin, dude was straight up with me that sold it to me, he's a daily user, daily shooter and he said, "I'm going to give you this shit. I'm going to say, you have to swear to me that you will not shoot it." And I didn't have to shoot at the time anyway, so you didn't have to worry about me doing that&#8221; (North Carolina, female, age 28).</p></disp-quote></p><p id="Par50">These trusted relationships that were built between participants and drug sellers served as protective in some cases, as participants would alter their drug use behaviors depending on what information was shared with them about the drugs they were selling, as the participant below explains.<disp-quote><p id="Par51">&#8220;I remember my dealer once got bags of fentanyl, and they knew it was fentanyl, and they told me just do one, and I did&#8221; (New England, male, age 29).</p></disp-quote></p></sec><sec id="Sec14"><title>Altering drug use practices</title><p id="Par52">Given the growing concern about fentanyl and many personal experiences with overdose, participants altered their drug use practices. This included avoiding injecting; using smaller amounts; tasting, smelling and/or examining drugs, and using drugs with other people.</p></sec><sec id="Sec15"><title>Avoiding injecting</title><p id="Par53">When participants were unsure about their drugs, but still wanted to use, they described doing so in ways that reduced the risk of fatal overdose. This often meant avoiding injecting.</p><p id="Par54">Said one woman, &#8220;<italic toggle="yes">If I'm concerned about it, if I'm told that it's just pure fentanyl-based, I'm not shooting [injecting] it&#8221;</italic> (North Carolina, female, age 28).</p><p id="Par55">Some participants recounted testing heroin by smoking it first and then making a decision to continue using the heroin by smoking or injection: &#8220;<italic toggle="yes">We smoked the heroin, any heroin we&#8217;ve got you smoke a little bit. Just inhale it, take a score and see what it is, &#8216;cause if you&#8217;re going to- I mean you can smoke the fentanyl</italic>&#8221; (Wisconsin, male, age 27).</p></sec><sec id="Sec16"><title>Testing small amounts of the drug</title><p id="Par56">Participants also discussed first using smaller amounts via injection.<disp-quote><p id="Par57">&#8220;Now whenever I use heroin, like if I'm with some people and we get a new batch, I'll guinea pig it because other people will do just ... they'll do a shot [inject] like they would ... like this dope was the same dope you had last week. Guess what? It's not, jackass. It's not. I would do a tenth of a tenth, a very small amount. Ten units of water. That's all I needed. Very small amount to gauge the potency. I'm pretty good at being able to tell. "Okay, this is ... whoa, be careful, guys. That's all I can tell you. Be very careful" (Illinois, male, age 25).</p></disp-quote></p></sec><sec id="Sec17"><title>Tasting, smelling, and/or examining drugs</title><p id="Par58">Participants also discussed using sensory methods to investigate their drugs. As described by one person, &#8220;<italic toggle="yes">I mean, usually most of the fentanyl-based heroin is going to be lighter in color. Most of the heroin here is brown&#8221;</italic> (North Carolina, female, age 43). Another woman said:<disp-quote><p id="Par59">&#8220;Straight heroin taste is a more vinegary flavor. The fentanyl doesn&#8217;t have that flavor. It doesn&#8217;t have the vinegary. You can also take a black light. If you have heroin, you can take a black light and it will florescent-green. It will florescent-green if it&#8217;s heroin&#8221; (Oregon, female, age 50-59).</p></disp-quote></p><p id="Par60">North Carolina had an important regional theme emerge where people discussed a type of heroin referred to as &#8220;Gray Death&#8221; that was potentially contaminated with fentanyl: <italic toggle="yes">&#8220;It was gravel. It was gray, it was gravel gray. I'm sure it had something in it. I didn't have a test strip, but I'm sure it had&#8221;</italic> (North Carolina, female, age 28). This was the only location that discussed gray heroin and should be explored more in future research.</p></sec><sec id="Sec18"><title>Using drugs with other people</title><p id="Par61">Another important strategy was using drugs with others so if someone overdosed help could be called and/or naloxone could be used and the overdose could be reversed.<disp-quote><p id="Par62"><italic toggle="yes">&#8220;When we did it the other day, the girl who brought it over, I watched her do it, saw how much she did. I just watched her and kept my eye on her for a few minutes afterwards to see how she was because I know with the stuff we were doing before, almost everybody would pretty much almost go out, just hardly even keep their eyes open. She just kept talking like a regular conversation, so it wasn't to a point where she couldn't continue to talk. Then my husband almost always does it first. I don't really know why we do that, but we just do&#8221;</italic> (North Carolina, female, age 49).</p></disp-quote></p></sec><sec id="Sec19"><title>Fentanyl test strips</title><p id="Par63">Fentanyl test strips can be used to detect the presence of fentanyl in drugs but they cannot quantify it [<xref ref-type="bibr" rid="CR33">33</xref>]. Not all participants knew about or had access to fentanyl test strips: <italic toggle="yes">&#8220;I have overdosed and it wasn't any more than I'm used to using, so I'm pretty positive that I've absolutely used fentanyl at some point in time. But I know now, they have those little fentanyl test strips and things like that. Getting access to them is virtually impossible</italic>&#8221; (North Carolina, male, age 38).</p><p id="Par64">However, another participant in North Carolina reported having access to fentanyl test strips.They explained how they would use them when they felt uncertain about their drugs: <italic toggle="yes">&#8220;I use test strips, I try to use test strips when I can&#8221;</italic> (North Carolina, female, age 28). This suggests that some participants in North Carolina had greater access to fentanyl test strips than others. More research should be conducted to understand who has increased access and why.</p><p id="Par65">Participants who obtained strips often got them from their local harm reduction organization. For example, a New England participant who was talking about familial drug use described how her older sister used fentanyl test strips and new injecting equipment from the syringe services program:<disp-quote><p id="Par66">&#8220;She gets, um, the fentanyl testers&#8230;she&#8217;s very like, she gets high, don&#8217;t get me wrong. But she&#8217;s very aware of what she&#8217;s getting high with. She&#8217;s not one of them that you&#8217;re just going to give her a bag and she&#8217;s going to do it. She&#8217;s like a scientist&#8221; (New England, female, age 38).</p></disp-quote></p></sec><sec id="Sec20"><title>Naloxone</title><p id="Par67">Awareness of and access to naloxone was described at most sites, although this varied. Participants in North Carolina exhibited the greatest awareness and access, and described carrying and using Narcan, a name brand of naloxone: &#8220;<italic toggle="yes">I always carry one in my purse and then I always have two in my car. Then we have some at home too</italic>&#8221; (North Carolina, female, age 25).</p><p id="Par68">Ensuring avoidance of a fatal overdose through the use of naloxone was well articulated among participants and their peers. Stated one woman, &#8220;<italic toggle="yes">A lot of people that got it [naloxone] have gone to [Agency] and gotten the kit, the Narcan kits&#8221;</italic> (New England, female, age 31). Another person said:<disp-quote><p id="Par69">&#8220;Our dealer who gave it to us said, &#8216;I&#8217;m not even giving this to you unless you have Narcan because I know it&#8217;s strong.&#8217; And we had it on us and I went and then within the same hour my boyfriend&#8217;s brother went. And it took two shots for me and five for him. That was a scary day, but we both came back&#8221; (Wisconsin, female, age 28).</p></disp-quote></p><p id="Par70">However, some participants noted that the presence of naloxone was less common in their rural area compared to urban settings:<disp-quote><p id="Par71">&#8220;Narcan is more common in bigger cities. In Champagne, everyone else at meetings, half of them were trained and had it on them. I used to. Down here, no. There's not a lot of a Narcan presence down here that I'm aware of personally. I could be wrong&#8221; (Illinois, male, age 27).</p></disp-quote></p><p id="Par72">These findings gesture to potential regional differences in naloxone availability or access at the time of this study. This could be due to harm reduction activism and infrastructures in each location.</p></sec></sec></sec><sec id="Sec21"><title>Discussion</title><p id="Par73">Participants in this study living in rural regions of the U.S.&#8211; regardless of location or type of drug used&#8211; described an awareness and growing concern that their drug supply was contaminated with fentanyl. They described worries about fentanyl in opioids, including counterfeit pills, as well as in stimulants, particularly methamphetamines, without their knowledge. Research has identified fentanyl in stimulants as a concern and risk for overdose, now termed &#8220;the fourth wave&#8221; of the overdose epidemic to be an increase in polydrug use that includes stimulant and opioid use [<xref ref-type="bibr" rid="CR80">80</xref>&#8211;<xref ref-type="bibr" rid="CR82">82</xref>]. This study adds context to that literature by describing the concerns and uncertainty of a large rural population who use drugs [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. Prior studies have found that rural areas are experiencing growing rates of methamphetamine use, both alone and in combination with other substances [<xref ref-type="bibr" rid="CR85">85</xref>] and 74% of survey respondents in the quantitative ROI study reported methamphetamine use in the past 30&#160;days [<xref ref-type="bibr" rid="CR73">73</xref>]. This finding highlights the need for targeted overdose prevention approaches for people who use stimulants and those who use multiple drugs. Those with concerns about fentanyl-contaminated methamphetamine took additional measures to protect themselves and others from overdose (Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Harm reduction organizations and services, by site 2018&#8211;2020</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Site</th><th align="left" colspan="1" rowspan="1">Harm Reduction Services</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">IL</td><td align="left" colspan="1" rowspan="1">1 syringe service program (SSP). The SSP had 2 fixed locations and operated a mobile unit that served the 16 southern counties of IL</td></tr><tr><td align="left" rowspan="2" colspan="1">KY</td><td align="left" colspan="1" rowspan="1">2 SSPs. Both were fixed locations located in 2 separate counties</td></tr><tr><td align="left" colspan="1" rowspan="1">An additional fixed location SSP opened near the end of the study, but most of the recruitment was complete so the results of this study likely do not reflect interactions with that SSP</td></tr><tr><td align="left" colspan="1" rowspan="1">NC</td><td align="left" colspan="1" rowspan="1">3 fixed location SSPs, 2 of which made limited deliveries. Fixed locations and deliveries spanned 4 counties</td></tr><tr><td align="left" colspan="1" rowspan="1">NE</td><td align="left" colspan="1" rowspan="1">5 fixed location SSPs, 4 of which offered mobile services. In total, the 5 SSPs served 7 out of the 11 counties included in this study site</td></tr><tr><td align="left" colspan="1" rowspan="1">OH</td><td align="left" colspan="1" rowspan="1">2 SSPs. Both were fixed locations in 2 different counties</td></tr><tr><td align="left" colspan="1" rowspan="1">OR</td><td align="left" colspan="1" rowspan="1">14 agencies provided SSP services. Services spanned 19 counties. There were 18 fixed location sights. One of the sites used a delivery model</td></tr><tr><td align="left" colspan="1" rowspan="1">WI</td><td align="left" colspan="1" rowspan="1">13 SSPs covering 20 counties of WI within the study catchment area. One out of the 13 SSPs had a mobile unit that served 8 counties (one county overlapped with a fixed location site)</td></tr><tr><td align="left" colspan="1" rowspan="1">WV</td><td align="left" colspan="1" rowspan="1">2 SSPs. One was a fixed location and the other mobile. They served 2 counties</td></tr></tbody></table><table-wrap-foot><p>Fixed location SSPs are reported as one county (the county they were located in. Although any participant could access those fixed locations due to transportation and other various barriers it was challenging to go out of one&#8217;s county</p></table-wrap-foot></table-wrap></p><p id="Par74">Participants who used opioids, stimulants, or both engaged in several individual and community-level harm reduction techniques to prevent fatal overdose, often using multiple approaches simultaneously. One common method was purchasing drugs from people they trusted. Participants recounted being warned about the possible presence and danger of fentanyl by trusted sellers who showed genuine concern for the buyers&#8217; wellbeing. Some people who sold drugs even supplied harm reduction tools, such as syringes, fentanyl test strips and naloxone. This finding echoes past research that found people who sell drugs often care about the people they sell to and actively try to prevent overdose or other drug related harms [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Findings from this large rural sample add significantly to our understanding of how people who sell drugs interact with their customers. Although sellers may not be aware of all the contaminants in the drugs they sell, both sellers and people who use drugs can alert others that overdoses have occurred from a particular supply or whether the supply tests positive for fentanyl [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>].</p><p id="Par75">These findings underscore that persons who sell drugs can, as social network members, be actors in improving health outcomes for people who use drugs [<xref ref-type="bibr" rid="CR88">88</xref>&#8211;<xref ref-type="bibr" rid="CR90">90</xref>]. Research suggests that laws criminalizing people who sell drugs do not reduce access to drugs, but may push people to buy drugs from unknown sellers, potentially increasing overdose risk [<xref ref-type="bibr" rid="CR91">91</xref>]. In fact, a recent study found that overdose clusters increased following police drug seizures [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. When people, including those selling drugs, are removed from their social networks the entire network can suffer and negative health outcomes can occur [<xref ref-type="bibr" rid="CR94">94</xref>]. Our findings suggest a potential opportunity to look for ways to optimize established social networks of people who use drugs to prevent overdose and disseminate harm reduction strategies. Providing people who sell and use drugs with resources to check their drugs would also be useful, helping both to better understand what is in the local drug supply and discuss drug-checking informed harm reduction approaches, as noted in a recent study in an urban setting [<xref ref-type="bibr" rid="CR95">95</xref>].</p><p id="Par76">Altering drug use behaviors was another harm reduction strategy described by participants. Participants (1) avoided injecting, (2) tested small amounts of their drug(s) before using, (3) tasted, smelled and/or looked at drugs to identify fentanyl, and (4) used drugs with other people. Using smaller amounts of drugs, often referred to as &#8220;test shots&#8221;, has been previously documented [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. People also can change the way they use by switching from injecting to snorting or smoking, which can reduce overdose risk [<xref ref-type="bibr" rid="CR98">98</xref>]. Research in Canada found that people reported looking for differences in &#8220;color, odour, taste&#8221; in their drugs to identify fentanyl and, if they were concerned, they would alert friends, but these techniques have proven ineffective in identifying fentanyl contamination [<xref ref-type="bibr" rid="CR99">99</xref>]. On the other hand, using with other people is an effective harm reduction strategy [<xref ref-type="bibr" rid="CR100">100</xref>] and was an important technique described by participants in this study since most fatalities occur among people who use drugs alone [<xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR102">102</xref>].</p><p id="Par77">Few participants mentioned fentanyl test strips, which can be used to detect the presence of fentanyl in drugs; however, this study was done just as fentanyl test strips were becoming available. This echoes other studies in rural areas that report a lack of awareness about fentanyl test strips [<xref ref-type="bibr" rid="CR96">96</xref>] and shows that the problem is widespread across rural areas of the U.S. Providing fentanyl test strips to people who use drugs, both stimulants and opioids [<xref ref-type="bibr" rid="CR103">103</xref>], is an approach to scale up overdose prevention efforts. However, fentanyl test strips only signal the presence of fentanyl and not its potency [<xref ref-type="bibr" rid="CR33">33</xref>]. At the very least, test strip detection of fentanyl can be used to indicate the need for additional harm reduction measures. Many people who use drugs in rural areas lack access to formal harm reduction services and other health supports [<xref ref-type="bibr" rid="CR47">47</xref>], making it difficult to obtain tools like fentanyl test strips. One way to increase accessibility to fentanyl test strips is by mailing them to people living in areas that lack access to harm reduction services [<xref ref-type="bibr" rid="CR104">104</xref>]. Fentanyl test strips could also be distributed in key social spaces, such as libraries, pharmacies, and vending machines in key locations [<xref ref-type="bibr" rid="CR105">105</xref>]. People who sell drugs could also distribute test strips.</p><p id="Par78">There have been community efforts to provide more sophisticated drug testing than fentanyl test strips alone. For example, the Urban Survivors Union based in Greenville, North Carolina, began using a drug-checking spectrometer to identify contaminants in the drug supply, and in 2022 the University of North Carolina launched a program to check drugs by mail program [<xref ref-type="bibr" rid="CR34">34</xref>]. Harm reduction agencies in urban locations have also begun to implement drug checking programs [<xref ref-type="bibr" rid="CR106">106</xref>]. Despite the effectiveness of this type of drug checking{Giulini, 2023 #7593}{Borden, 2022 #7592}, and its wide acceptability internationally, the U.S. has had limited uptake [<xref ref-type="bibr" rid="CR107">107</xref>]. There has also been an increase in the presence of the veterinary sedative xylazine in drug samples that causes necrotic soft tissue ulcerations [<xref ref-type="bibr" rid="CR108">108</xref>] and increases the risk of overdose, among other health complications [<xref ref-type="bibr" rid="CR109">109</xref>, <xref ref-type="bibr" rid="CR110">110</xref>], and test strips for this agent are now available. Given that contaminants in the drug supply is an ongoing and evolving problem, access to more sophisticated drug checking is critical.</p><p id="Par79">In regard to naloxone, we identified an important potential regional difference. While North Carolina participants seemed to have more access and experience using naloxone, this regional difference could be related to how questions were asked in the qualitative interview (see qualitative guide in Online Appendix). The quantitative ROI findings reported that 53% of survey respondents ever received &#8220;an overdose reversal kit or prescription for naloxone or Narcan&#8221; [<xref ref-type="bibr" rid="CR73">73</xref>] and the New England site reported that 43% of survey respondents had used naloxone to reverse an overdose [<xref ref-type="bibr" rid="CR111">111</xref>]. Sixty-seven percent of survey respondents in North Carolina reported ever receiving an overdose reversal kit or prescription for naloxone, and while this percentage is higher than the average, it was not the highest percentage reported; in Ohio, 72% of survey respondents reported ever receiving an overdose reversal kit or prescription for naloxone or Narcan [<xref ref-type="bibr" rid="CR73">73</xref>].</p><p id="Par80">Interestingly, one participant from Wisconsin mentioned receiving naloxone from the person from whom they purchase drugs, suggesting that in the absence of structured harm reduction efforts, people who sell and use drugs may work together to develop strategies to prevent fatal overdose. Of note, naloxone can be costly and access to affordable or free naloxone is critical [<xref ref-type="bibr" rid="CR112">112</xref>]. Similar to our drug-checking findings, this study highlights the importance of increasing awareness and accessibility to naloxone in rural areas. Two strategies for achieving this aim are collaboration with harm reduction organizations and, in particularly resource-scarce settings, through mail-ordered naloxone.</p><p id="Par81">This study has several limitations. The ROI funded initiative was developed in 2015 and data collected between 2018 and 2020; causes of overdose fatalities have changed over time and the results of the current study reflect the 4th wave and may not reflect the current state, when most overdose fatalities involve multiple substances. The sample is comprised of predominantly white participants which were the majority of residents in the study areas. Future studies should include a more racially and ethnically diverse sample of rural people who use drugs, as their experiences may differ significantly. Additionally, focusing on other characteristics, such as gender, sexuality, and disability, will be important to understand what subpopulations of people who use drugs need to prevent overdose [<xref ref-type="bibr" rid="CR113">113</xref>]. The increase in people under 30&#160;years of age experiencing overdose suggests that future studies may consider oversampling younger adults [<xref ref-type="bibr" rid="CR114">114</xref>]. Rural areas within this study are diverse, and variations in geographical, economic, and social factors can lead to significant differences between different rural regions. There were differences in micropolitan areas within some rural regions and more accessibility to micropolitan settings depending on location, which could have impacted access to harm reduction supplies. We do not know if people who sell drugs were in our sample, as we did not ask specific questions about sales experience. Future studies might consider exploring how people who sell drugs use harm reduction methods to prevent overdose for themselves and for their customers. Because interviews were conducted before the COVID-19 pandemic, this study cannot assess COVID&#8217;s impact on overdose risk nor harm reduction approaches to prevent overdose. However, recent studies in some of the rural areas represented in this study argue that overdose risk increased after the onset of the pandemic. For example, drug markets were altered, people experienced increased isolation, and community services were disrupted [<xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref>]. Further, the pandemic also disrupted drug markets, removing trusted people who sell drugs, and increasing risks associated with buying drugs from unknown sources [<xref ref-type="bibr" rid="CR115">115</xref>]. There may also have been changes in harm reduction since the interviews were conducted before the COVID-19 pandemic, such as increased access to naloxone and fentanyl test strips. Our interview guide had the following limitations: First, although our guides were harmonized, there were differences at each research site (e.g., recruitment criteria, community drug use trends) that could have influenced variation in responses. Second, the guide did not ask specific behavioral harm reduction questions. Third, interview probes to explore harm reduction as it pertained to fentanyl use were included only with the question regarding injection drug use, which could have resulted in missing information about fentanyl use from people who did not inject drugs and having less nuance regarding other harm reduction details. Fourth, although we asked about local conditions in the interviews, we did not have probes specific to geography and harm reduction. Thus, few geographic differences emerged in participants&#8217; discussion of harm reduction strategies. Finally, given the predominance of community engaged research and sampling methods and the partnership with harm reduction organizations, study participants who were engaged in harm reduction services and practices may have been overrepresented.</p></sec><sec id="Sec22"><title>Conclusion</title><p id="Par82">This study provides nuanced insight into harm reduction strategies adopted by people who use drugs in a large, regionally diverse United States rural sample. The rural landscape in the United States is incredibly diverse, and variations in geographical, economic, and social factors can lead to significant differences between different rural regions. In the context of our paper, disparities in infrastructure, resources, and access to essential services are notable. However, few regional differences emerged in participants&#8217; discussion of harm reduction strategies. This paper finds that rural people who use drugs experience different risk environments [<xref ref-type="bibr" rid="CR116">116</xref>] compared to their urban peers and points to the importance of understanding how local contexts shape harm reduction approaches. Many harm reduction strategies have emerged as community responses to protect oneself and others from a fatal overdose, particularly in locations where the absence of formal prevention efforts led by local, state, or federal agencies are limited or missing altogether. Multiple harm reduction strategies were often used in tandem and influenced drug use behaviors.</p></sec><sec sec-type="supplementary-material"><sec id="Sec23"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12954_2024_1062_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file 1</p></caption></media></supplementary-material></p></sec></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author Contribution</title><p>All authors except DF re-coded the DCC. SW prepared the manuscript. All authors reviewed and edited multiple drafts.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>National Institute on Drug Abuse (NIDA) [grant numbers K01DA053159, PI: Walters; MPIs: 4UH3DA044829-03 Pho, Jenkins; 1UG3DA044830, 4UH3DA044380, MPIs: Friedmann, Stopka; UG3DA044825, UH3DA044830; MPIs: Feinberg, Smith; UG3 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="DA044831">DA044831</ext-link>, UH3 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="DA044831">DA044831</ext-link>, UL1TR002369, PI Korthuis; 5UH3DA044822, MPIs: Go, Miller; 5UH3DA044826, MPIs: Seal, Westergaard; UG3 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="DA044798">DA044798</ext-link>/UH3 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="DA044798">DA044798</ext-link>, MPIs: Cooper, Young; UH3DA044823, PI: Zule: R25DA037190 (The Lifespan/Brown Criminal Justice Research Training Program on Substance Use and HIV). The authors thank the other ROI investigators and their teams, the ROI Executive Steering Committee chair, Dr. Holly Hagan, the NIDA Science Officer, Dr. Richard Jenkins, and particularly, the participants of the individual ROI studies for their valuable contributions. A full list of participating ROI investigators and institutions can be found on the ROI website at&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ruralopioidinitiative.org/studies.html">http://ruralopioidinitiative.org/studies.html</ext-link>. No funders were involved in the preparation of this manuscript or the decision to submit for publication.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The data from this study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par83">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Gumas ED, Baumgartner JC. &#8220;U.S. Overdose Deaths Remain Higher Than in Other Countries &#8212; How Harm-Reduction Programs Could Help. To the Point (blog), Commonwealth Fund, June 22, 2023. 10.26099/0eb5-9d85</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Hedegaard H, Mini&#241;o A, Spencer MR, Warner M. Drug overdose deaths in the United States, 1999&#8211;2020. NCHS data brief. 2022(428).<pub-id pub-id-type="pmid">34978529</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomes</surname><given-names>T</given-names></name><name name-style="western"><surname>Ledlie</surname><given-names>S</given-names></name><name name-style="western"><surname>Tadrous</surname><given-names>M</given-names></name><name name-style="western"><surname>Mamdani</surname><given-names>M</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>JM</given-names></name><name name-style="western"><surname>Juurlink</surname><given-names>DN</given-names></name></person-group><article-title>Trends in opioid toxicity-related deaths in the US before and after the start of the COVID-19 Pandemic, 2011&#8211;2021</article-title><source>JAMA Netw Open.</source><year>2023</year><volume>6</volume><issue>7</issue><fpage>e2322303</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.22303</pub-id><pub-id pub-id-type="pmid">37418260</pub-id><pub-id pub-id-type="pmcid">PMC10329206</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Gomes T, Ledlie S, Tadrous M, Mamdani M, Paterson JM, Juurlink DN. Trends in opioid toxicity-related deaths in the US before and after the start of the COVID-19 Pandemic, 2011&#8211;2021. JAMA Netw Open. 2023;6(7):e2322303.<pub-id pub-id-type="pmid">37418260</pub-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.22303</pub-id><pub-id pub-id-type="pmcid">PMC10329206</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spencer</surname><given-names>MR</given-names></name><name name-style="western"><surname>Mini&#241;o</surname><given-names>AM</given-names></name><name name-style="western"><surname>Warner</surname><given-names>M</given-names></name></person-group><article-title>Drug overdose deaths in the United States, 2001&#8211;2021</article-title><source>NCHS Data Brief.</source><year>2022</year><volume>457</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">36598401</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Spencer MR, Mini&#241;o AM, Warner M. Drug overdose deaths in the United States, 2001&#8211;2021. NCHS Data Brief. 2022;457:1&#8211;8.<pub-id pub-id-type="pmid">36598401</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Centers for Disease Control and Prevention. National Vital Statistics System. Provisional Drug Overdose Death Counts. Accessed: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm">https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm</ext-link></mixed-citation></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciccarone</surname><given-names>D</given-names></name></person-group><article-title>The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis</article-title><source>Curr Opin Psychiatry</source><year>2021</year><volume>34</volume><issue>4</issue><fpage>344</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1097/YCO.0000000000000717</pub-id><pub-id pub-id-type="pmid">33965972</pub-id><pub-id pub-id-type="pmcid">PMC8154745</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344&#8211;50.<pub-id pub-id-type="pmid">33965972</pub-id><pub-id pub-id-type="doi">10.1097/YCO.0000000000000717</pub-id><pub-id pub-id-type="pmcid">PMC8154745</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>CM</given-names></name><name name-style="western"><surname>Einstein</surname><given-names>EB</given-names></name><name name-style="western"><surname>Compton</surname><given-names>WM</given-names></name></person-group><article-title>Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010&#8211;2016</article-title><source>JAMA.</source><year>2018</year><volume>319</volume><issue>17</issue><fpage>1819</fpage><pub-id pub-id-type="doi">10.1001/jama.2018.2844</pub-id><pub-id pub-id-type="pmid">29715347</pub-id><pub-id pub-id-type="pmcid">PMC6583033</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Jones CM, Einstein EB, Compton WM. Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010&#8211;2016. JAMA. 2018;319(17):1819.<pub-id pub-id-type="pmid">29715347</pub-id><pub-id pub-id-type="doi">10.1001/jama.2018.2844</pub-id><pub-id pub-id-type="pmcid">PMC6583033</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez</surname><given-names>S</given-names></name><name name-style="western"><surname>Jones</surname><given-names>JD</given-names></name><name name-style="western"><surname>Brandt</surname><given-names>L</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>ANC</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>R</given-names></name><name name-style="western"><surname>Comer</surname><given-names>SD</given-names></name></person-group><article-title>The increasing prevalence of fentanyl: a urinalysis-based study among individuals with opioid use disorder in New York City</article-title><source>The American Journal on Addictions.</source><year>2021</year><volume>30</volume><issue>1</issue><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1111/ajad.13092</pub-id><pub-id pub-id-type="pmid">32776640</pub-id><pub-id pub-id-type="pmcid">PMC7816517</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Martinez S, Jones JD, Brandt L, Campbell ANC, Abbott R, Comer SD. The increasing prevalence of fentanyl: a urinalysis-based study among individuals with opioid use disorder in New York City. The American Journal on Addictions. 2021;30(1):65&#8211;71.<pub-id pub-id-type="pmid">32776640</pub-id><pub-id pub-id-type="doi">10.1111/ajad.13092</pub-id><pub-id pub-id-type="pmcid">PMC7816517</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLean</surname><given-names>K</given-names></name><name name-style="western"><surname>Monnat</surname><given-names>SM</given-names></name><name name-style="western"><surname>Rigg</surname><given-names>K</given-names></name><name name-style="western"><surname>Sterner</surname><given-names>GE</given-names></name><name name-style="western"><surname>Verdery</surname><given-names>A</given-names></name></person-group><article-title>&#8220;You never know what you&#8217;re getting&#8221;: opioid users&#8217; perceptions of fentanyl in Southwest Pennsylvania</article-title><source>Subst Use Misuse</source><year>2019</year><volume>54</volume><issue>6</issue><fpage>955</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1080/10826084.2018.1552303</pub-id><pub-id pub-id-type="pmid">30676198</pub-id><pub-id pub-id-type="pmcid">PMC6476660</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">McLean K, Monnat SM, Rigg K, Sterner GE, Verdery A. &#8220;You never know what you&#8217;re getting&#8221;: opioid users&#8217; perceptions of fentanyl in Southwest Pennsylvania. Subst Use Misuse. 2019;54(6):955&#8211;66.<pub-id pub-id-type="pmid">30676198</pub-id><pub-id pub-id-type="doi">10.1080/10826084.2018.1552303</pub-id><pub-id pub-id-type="pmcid">PMC6476660</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rouhani</surname><given-names>S</given-names></name><name name-style="western"><surname>Park</surname><given-names>JN</given-names></name><name name-style="western"><surname>Morales</surname><given-names>KB</given-names></name><name name-style="western"><surname>Green</surname><given-names>TC</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>SG</given-names></name></person-group><article-title>Harm reduction measures employed by people using opioids with suspected fentanyl exposure in Boston, Baltimore, and Providence</article-title><source>Harm Reduct J.</source><year>2019</year><volume>16</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/s12954-019-0311-9</pub-id><pub-id pub-id-type="pmid">31234942</pub-id><pub-id pub-id-type="pmcid">PMC6591810</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Rouhani S, Park JN, Morales KB, Green TC, Sherman SG. Harm reduction measures employed by people using opioids with suspected fentanyl exposure in Boston, Baltimore, and Providence. Harm Reduct J. 2019;16(1):1&#8211;9.<pub-id pub-id-type="pmid">31234942</pub-id><pub-id pub-id-type="doi">10.1186/s12954-019-0311-9</pub-id><pub-id pub-id-type="pmcid">PMC6591810</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>CM</given-names></name><name name-style="western"><surname>Compton</surname><given-names>WM</given-names></name><name name-style="western"><surname>Mustaquim</surname><given-names>D</given-names></name></person-group><article-title>Patterns and characteristics of methamphetamine use among adults&#8212;United States, 2015&#8211;2018</article-title><source>Morb Mortal Wkl Rep</source><year>2020</year><volume>69</volume><issue>12</issue><fpage>317</fpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6912a1</pub-id><pub-id pub-id-type="pmcid">PMC7725509</pub-id><pub-id pub-id-type="pmid">32214077</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Jones CM, Compton WM, Mustaquim D. Patterns and characteristics of methamphetamine use among adults&#8212;United States, 2015&#8211;2018. Morb Mortal Wkl Rep. 2020;69(12):317.<pub-id pub-id-type="doi">10.15585/mmwr.mm6912a1</pub-id><pub-id pub-id-type="pmcid">PMC7725509</pub-id><pub-id pub-id-type="pmid">32214077</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>RL</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J</given-names></name><name name-style="western"><surname>Edgerton</surname><given-names>R</given-names></name><name name-style="western"><surname>Watson</surname><given-names>J</given-names></name><name name-style="western"><surname>MacMaster</surname><given-names>SA</given-names></name><name name-style="western"><surname>Kalliny</surname><given-names>M</given-names></name><etal/></person-group><article-title>Modeling dynamics of fatal opioid overdose by state and across time</article-title><source>Prev Med Rep</source><year>2020</year><volume>20</volume><fpage>101184</fpage><pub-id pub-id-type="doi">10.1016/j.pmedr.2020.101184</pub-id><pub-id pub-id-type="pmid">32995141</pub-id><pub-id pub-id-type="pmcid">PMC7516293</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Cooper RL, Thompson J, Edgerton R, Watson J, MacMaster SA, Kalliny M, et al. Modeling dynamics of fatal opioid overdose by state and across time. Prev Med Rep. 2020;20:101184.<pub-id pub-id-type="pmid">32995141</pub-id><pub-id pub-id-type="doi">10.1016/j.pmedr.2020.101184</pub-id><pub-id pub-id-type="pmcid">PMC7516293</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furr-Holden</surname><given-names>D</given-names></name><name name-style="western"><surname>Milam</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Sadler</surname><given-names>R</given-names></name></person-group><article-title>African Americans now outpace whites in opioid-involved overdose deaths: a comparison of temporal trends from 1999 to 2018</article-title><source>Addiction</source><year>2021</year><volume>116</volume><issue>3</issue><fpage>677</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1111/add.15233</pub-id><pub-id pub-id-type="pmid">32852864</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Furr-Holden D, Milam AJ, Wang L, Sadler R. African Americans now outpace whites in opioid-involved overdose deaths: a comparison of temporal trends from 1999 to 2018. Addiction. 2021;116(3):677&#8211;83.<pub-id pub-id-type="pmid">32852864</pub-id><pub-id pub-id-type="doi">10.1111/add.15233</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cano</surname><given-names>M</given-names></name></person-group><article-title>Racial/ethnic differences in US drug overdose mortality, 2017&#8211;2018</article-title><source>Addict Behav</source><year>2021</year><volume>112</volume><fpage>106625</fpage><pub-id pub-id-type="doi">10.1016/j.addbeh.2020.106625</pub-id><pub-id pub-id-type="pmid">32916612</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Cano M. Racial/ethnic differences in US drug overdose mortality, 2017&#8211;2018. Addict Behav. 2021;112:106625.<pub-id pub-id-type="pmid">32916612</pub-id><pub-id pub-id-type="doi">10.1016/j.addbeh.2020.106625</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kariisa</surname><given-names>M</given-names></name><name name-style="western"><surname>Davis</surname><given-names>NL</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Seth</surname><given-names>P</given-names></name><name name-style="western"><surname>Mattson</surname><given-names>CL</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>F</given-names></name><etal/></person-group><article-title>Vital signs: drug overdose deaths, by selected sociodemographic and social determinants of health characteristics&#8212;25 states and the District of Columbia, 2019&#8211;2020</article-title><source>Morb Mortal Wkl Rep</source><year>2022</year><volume>71</volume><issue>29</issue><fpage>940</fpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7129e2</pub-id><pub-id pub-id-type="pmcid">PMC9310633</pub-id><pub-id pub-id-type="pmid">35862289</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Kariisa M, Davis NL, Kumar S, Seth P, Mattson CL, Chowdhury F, et al. Vital signs: drug overdose deaths, by selected sociodemographic and social determinants of health characteristics&#8212;25 states and the District of Columbia, 2019&#8211;2020. Morb Mortal Wkl Rep. 2022;71(29):940.<pub-id pub-id-type="doi">10.15585/mmwr.mm7129e2</pub-id><pub-id pub-id-type="pmcid">PMC9310633</pub-id><pub-id pub-id-type="pmid">35862289</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattson</surname><given-names>CL</given-names></name><name name-style="western"><surname>Tanz</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>K</given-names></name><name name-style="western"><surname>Kariisa</surname><given-names>M</given-names></name><name name-style="western"><surname>Patel</surname><given-names>P</given-names></name><name name-style="western"><surname>Davis</surname><given-names>NL</given-names></name></person-group><article-title>Trends and geographic patterns in drug and synthetic opioid overdose deaths&#8212;United States, 2013&#8211;2019</article-title><source>Morb Mortal Wkl Rep</source><year>2021</year><volume>70</volume><issue>6</issue><fpage>202</fpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7006a4</pub-id><pub-id pub-id-type="pmcid">PMC7877587</pub-id><pub-id pub-id-type="pmid">33571180</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths&#8212;United States, 2013&#8211;2019. Morb Mortal Wkl Rep. 2021;70(6):202.<pub-id pub-id-type="doi">10.15585/mmwr.mm7006a4</pub-id><pub-id pub-id-type="pmcid">PMC7877587</pub-id><pub-id pub-id-type="pmid">33571180</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walters</surname><given-names>S</given-names></name></person-group><article-title>COVID-19 and people who use drugs&#8212;a commentary</article-title><source>Health Behav Policy Rev</source><year>2020</year><volume>7</volume><issue>5</issue><fpage>489</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.14485/HBPR.7.5.11</pub-id><pub-id pub-id-type="pmid">33134405</pub-id><pub-id pub-id-type="pmcid">PMC7595339</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Walters S. COVID-19 and people who use drugs&#8212;a commentary. Health Behav Policy Rev. 2020;7(5):489&#8211;97.<pub-id pub-id-type="pmid">33134405</pub-id><pub-id pub-id-type="doi">10.14485/HBPR.7.5.11</pub-id><pub-id pub-id-type="pmcid">PMC7595339</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jenkins</surname><given-names>WD</given-names></name><name name-style="western"><surname>Bolinski</surname><given-names>R</given-names></name><name name-style="western"><surname>Bresett</surname><given-names>J</given-names></name><name name-style="western"><surname>Van Ham</surname><given-names>B</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>S</given-names></name><name name-style="western"><surname>Walters</surname><given-names>S</given-names></name><etal/></person-group><article-title>COVID-19 during the opioid epidemic - exacerbation of stigma and vulnerabilities</article-title><source>J Rural Health.</source><year>2020</year><volume>37</volume><fpage>172</fpage><pub-id pub-id-type="doi">10.1111/jrh.12442</pub-id><pub-id pub-id-type="pmid">32277731</pub-id><pub-id pub-id-type="pmcid">PMC7262104</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Jenkins WD, Bolinski R, Bresett J, Van Ham B, Fletcher S, Walters S, et al. COVID-19 during the opioid epidemic - exacerbation of stigma and vulnerabilities. J Rural Health. 2020;37:172.<pub-id pub-id-type="pmid">32277731</pub-id><pub-id pub-id-type="doi">10.1111/jrh.12442</pub-id><pub-id pub-id-type="pmcid">PMC7262104</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walters</surname><given-names>SM</given-names></name><name name-style="western"><surname>Bolinski</surname><given-names>RS</given-names></name><name name-style="western"><surname>Almirol</surname><given-names>E</given-names></name><name name-style="western"><surname>Grundy</surname><given-names>S</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>S</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>J</given-names></name><etal/></person-group><article-title>Structural and community changes during COVID-19 and their effects on overdose precursors among rural people who use drugs: a mixed-methods analysis</article-title><source>Addict Sci Clin Pract</source><year>2022</year><volume>17</volume><issue>1</issue><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/s13722-022-00303-8</pub-id><pub-id pub-id-type="pmid">35468860</pub-id><pub-id pub-id-type="pmcid">PMC9037978</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Walters SM, Bolinski RS, Almirol E, Grundy S, Fletcher S, Schneider J, et al. Structural and community changes during COVID-19 and their effects on overdose precursors among rural people who use drugs: a mixed-methods analysis. Addict Sci Clin Pract. 2022;17(1):24.<pub-id pub-id-type="pmid">35468860</pub-id><pub-id pub-id-type="doi">10.1186/s13722-022-00303-8</pub-id><pub-id pub-id-type="pmcid">PMC9037978</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolinski</surname><given-names>RS</given-names></name><name name-style="western"><surname>Walters</surname><given-names>S</given-names></name><name name-style="western"><surname>Salisbury-Afshar</surname><given-names>E</given-names></name><name name-style="western"><surname>Ouellet</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>WD</given-names></name><name name-style="western"><surname>Almirol</surname><given-names>E</given-names></name><etal/></person-group><article-title>The Impact of the COVID-19 pandemic on drug use behaviors, fentanyl exposure, and harm reduction service support among people who use drugs in rural settings</article-title><source>Int J Environ Res Public Health.</source><year>2022</year><volume>19</volume><issue>4</issue><fpage>2230</fpage><pub-id pub-id-type="doi">10.3390/ijerph19042230</pub-id><pub-id pub-id-type="pmid">35206421</pub-id><pub-id pub-id-type="pmcid">PMC8872091</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Bolinski RS, Walters S, Salisbury-Afshar E, Ouellet LJ, Jenkins WD, Almirol E, et al. The Impact of the COVID-19 pandemic on drug use behaviors, fentanyl exposure, and harm reduction service support among people who use drugs in rural settings. Int J Environ Res Public Health. 2022;19(4):2230.<pub-id pub-id-type="pmid">35206421</pub-id><pub-id pub-id-type="doi">10.3390/ijerph19042230</pub-id><pub-id pub-id-type="pmcid">PMC8872091</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mateu-Gelabert</surname><given-names>P</given-names></name><name name-style="western"><surname>Guarino</surname><given-names>H</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>K</given-names></name><name name-style="western"><surname>Meylakhs</surname><given-names>P</given-names></name><name name-style="western"><surname>Campos</surname><given-names>S</given-names></name><name name-style="western"><surname>Meylakhs</surname><given-names>A</given-names></name><etal/></person-group><article-title>Young drug users: a vulnerable population and an underutilized resource in HIV/HCV prevention</article-title><source>Curr HIV/AIDS Rep.</source><year>2018</year><volume>15</volume><issue>4</issue><fpage>324</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1007/s11904-018-0406-z</pub-id><pub-id pub-id-type="pmid">29931468</pub-id><pub-id pub-id-type="pmcid">PMC6309604</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Mateu-Gelabert P, Guarino H, Quinn K, Meylakhs P, Campos S, Meylakhs A, et al. Young drug users: a vulnerable population and an underutilized resource in HIV/HCV prevention. Curr HIV/AIDS Rep. 2018;15(4):324&#8211;35.<pub-id pub-id-type="pmid">29931468</pub-id><pub-id pub-id-type="doi">10.1007/s11904-018-0406-z</pub-id><pub-id pub-id-type="pmcid">PMC6309604</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mateu-Gelabert</surname><given-names>P</given-names></name><name name-style="western"><surname>Bolyard</surname><given-names>M</given-names></name><name name-style="western"><surname>Maslow</surname><given-names>C</given-names></name><name name-style="western"><surname>Sandoval</surname><given-names>M</given-names></name><name name-style="western"><surname>Flom</surname><given-names>PL</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>SR</given-names></name></person-group><article-title>For the common good: measuring residents' efforts to protect their community from drug- and sex-related harm</article-title><source>Sahara J.</source><year>2008</year><volume>5</volume><issue>3</issue><fpage>144</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1080/17290376.2008.9724913</pub-id><pub-id pub-id-type="pmid">18979048</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Mateu-Gelabert P, Bolyard M, Maslow C, Sandoval M, Flom PL, Friedman SR. For the common good: measuring residents&#8217; efforts to protect their community from drug- and sex-related harm. Sahara J. 2008;5(3):144&#8211;57.<pub-id pub-id-type="pmid">18979048</pub-id><pub-id pub-id-type="doi">10.1080/17290376.2008.9724913</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Mateu-Gelabert</surname><given-names>P</given-names></name><name name-style="western"><surname>Sandoval</surname><given-names>M</given-names></name></person-group><article-title>Group sex events amongst non-gay drug users: an understudied risk environment</article-title><source>Int J Drug Policy.</source><year>2011</year><volume>22</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2010.06.004</pub-id><pub-id pub-id-type="pmid">20800465</pub-id><pub-id pub-id-type="pmcid">PMC3019255</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Friedman SR, Mateu-Gelabert P, Sandoval M. Group sex events amongst non-gay drug users: an understudied risk environment. Int J Drug Policy. 2011;22(1):1&#8211;8.<pub-id pub-id-type="pmid">20800465</pub-id><pub-id pub-id-type="doi">10.1016/j.drugpo.2010.06.004</pub-id><pub-id pub-id-type="pmcid">PMC3019255</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Maslow</surname><given-names>C</given-names></name><name name-style="western"><surname>Bolyard</surname><given-names>M</given-names></name><name name-style="western"><surname>Sandoval</surname><given-names>M</given-names></name><name name-style="western"><surname>Mateu-Gelabert</surname><given-names>P</given-names></name><name name-style="western"><surname>Neaigus</surname><given-names>A</given-names></name></person-group><article-title>Urging others to be healthy: "intravention" by injection drug users as a community prevention goal</article-title><source>AIDS Educ Prev.</source><year>2004</year><volume>16</volume><issue>3</issue><fpage>250</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1521/aeap.16.3.250.35439</pub-id><pub-id pub-id-type="pmid">15237054</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Friedman SR, Maslow C, Bolyard M, Sandoval M, Mateu-Gelabert P, Neaigus A. Urging others to be healthy: &#8220;intravention&#8221; by injection drug users as a community prevention goal. AIDS Educ Prev. 2004;16(3):250&#8211;63.<pub-id pub-id-type="pmid">15237054</pub-id><pub-id pub-id-type="doi">10.1521/aeap.16.3.250.35439</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Bolyard</surname><given-names>M</given-names></name><name name-style="western"><surname>Maslow</surname><given-names>C</given-names></name><name name-style="western"><surname>Mateu-Gelabert</surname><given-names>P</given-names></name><name name-style="western"><surname>Sandoval</surname><given-names>M</given-names></name></person-group><article-title>Harnessing the power of social networks to reduce HIV risk</article-title><source>Focus.</source><year>2005</year><volume>20</volume><issue>1</issue><fpage>5</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15776521</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Friedman SR, Bolyard M, Maslow C, Mateu-Gelabert P, Sandoval M. Harnessing the power of social networks to reduce HIV risk. Focus. 2005;20(1):5&#8211;6.<pub-id pub-id-type="pmid">15776521</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>J</given-names></name><name name-style="western"><surname>Michaels</surname><given-names>S</given-names></name><name name-style="western"><surname>Bouris</surname><given-names>A</given-names></name></person-group><article-title>Family network proportion and HIV risk among black men who have sex with men</article-title><source>J Acquir Immune Defic Syndr.</source><year>2012</year><volume>61</volume><issue>5</issue><fpage>627</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e318270d3cb</pub-id><pub-id pub-id-type="pmid">23011395</pub-id><pub-id pub-id-type="pmcid">PMC3508259</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Schneider J, Michaels S, Bouris A. Family network proportion and HIV risk among black men who have sex with men. J Acquir Immune Defic Syndr. 2012;61(5):627&#8211;35.<pub-id pub-id-type="pmid">23011395</pub-id><pub-id pub-id-type="doi">10.1097/QAI.0b013e318270d3cb</pub-id><pub-id pub-id-type="pmcid">PMC3508259</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>AN</given-names></name><name name-style="western"><surname>Laumann</surname><given-names>EO</given-names></name></person-group><article-title>A new HIV prevention network approach: sociometric peer change agent selection</article-title><source>Soc Sci Med.</source><year>2015</year><volume>125</volume><fpage>192</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.socscimed.2013.12.034</pub-id><pub-id pub-id-type="pmid">24518188</pub-id><pub-id pub-id-type="pmcid">PMC4117829</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Schneider JA, Zhou AN, Laumann EO. A new HIV prevention network approach: sociometric peer change agent selection. Soc Sci Med. 2015;125:192&#8211;202.<pub-id pub-id-type="pmid">24518188</pub-id><pub-id pub-id-type="doi">10.1016/j.socscimed.2013.12.034</pub-id><pub-id pub-id-type="pmcid">PMC4117829</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Rich</surname><given-names>JD</given-names></name><name name-style="western"><surname>Green</surname><given-names>TC</given-names></name></person-group><article-title>The protective effect of trusted dealers against opioid overdose in the US</article-title><source>Int J Drug Policy.</source><year>2020</year><volume>78</volume><fpage>102695</fpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2020.102695</pub-id><pub-id pub-id-type="pmid">32143185</pub-id><pub-id pub-id-type="pmcid">PMC7302982</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Carroll JJ, Rich JD, Green TC. The protective effect of trusted dealers against opioid overdose in the US. Int J Drug Policy. 2020;78:102695.<pub-id pub-id-type="pmid">32143185</pub-id><pub-id pub-id-type="doi">10.1016/j.drugpo.2020.102695</pub-id><pub-id pub-id-type="pmcid">PMC7302982</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kral</surname><given-names>AH</given-names></name><name name-style="western"><surname>Lambdin</surname><given-names>BH</given-names></name><name name-style="western"><surname>Browne</surname><given-names>EN</given-names></name><name name-style="western"><surname>Wenger</surname><given-names>LD</given-names></name><name name-style="western"><surname>Bluthenthal</surname><given-names>RN</given-names></name><name name-style="western"><surname>Zibbell</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Transition from injecting opioids to smoking fentanyl in San Francisco</article-title><source>California. Drug and alcohol dependence.</source><year>2021</year><volume>227</volume><fpage>109003</fpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.109003</pub-id><pub-id pub-id-type="pmid">34482046</pub-id><pub-id pub-id-type="pmcid">PMC10790652</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Kral AH, Lambdin BH, Browne EN, Wenger LD, Bluthenthal RN, Zibbell JE, et al. Transition from injecting opioids to smoking fentanyl in San Francisco. California Drug and alcohol dependence. 2021;227: 109003.<pub-id pub-id-type="pmid">34482046</pub-id><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.109003</pub-id><pub-id pub-id-type="pmcid">PMC10790652</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mars</surname><given-names>SG</given-names></name><name name-style="western"><surname>Ondocsin</surname><given-names>J</given-names></name><name name-style="western"><surname>Ciccarone</surname><given-names>D</given-names></name></person-group><article-title>Toots, tastes and tester shots: user accounts of drug sampling methods for gauging heroin potency</article-title><source>Harm Reduct J</source><year>2018</year><volume>15</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s12954-018-0232-z</pub-id><pub-id pub-id-type="pmid">29769132</pub-id><pub-id pub-id-type="pmcid">PMC5956544</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Mars SG, Ondocsin J, Ciccarone D. Toots, tastes and tester shots: user accounts of drug sampling methods for gauging heroin potency. Harm Reduct J. 2018;15(1):1&#8211;10.<pub-id pub-id-type="pmid">29769132</pub-id><pub-id pub-id-type="doi">10.1186/s12954-018-0232-z</pub-id><pub-id pub-id-type="pmcid">PMC5956544</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Stewart</surname><given-names>B</given-names></name></person-group><source>Demand for fentanyl test strips booms&#8212;but test is not widely available</source><year>2017</year><publisher-loc>Toronto</publisher-loc><publisher-name>CBC News</publisher-name></element-citation><mixed-citation id="mc-CR31" publication-type="book">Stewart B. Demand for fentanyl test strips booms&#8212;but test is not widely available. Toronto: CBC News; 2017.</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciccarone</surname><given-names>D</given-names></name></person-group><article-title>Fentanyl in the US heroin supply: a rapidly changing risk environment</article-title><source>Int J Drug Policy</source><year>2017</year><volume>46</volume><fpage>107</fpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2017.06.010</pub-id><pub-id pub-id-type="pmid">28735776</pub-id><pub-id pub-id-type="pmcid">PMC5742018</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Ciccarone D. Fentanyl in the US heroin supply: a rapidly changing risk environment. Int J Drug Policy. 2017;46:107.<pub-id pub-id-type="pmid">28735776</pub-id><pub-id pub-id-type="doi">10.1016/j.drugpo.2017.06.010</pub-id><pub-id pub-id-type="pmcid">PMC5742018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palamar</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Salomone</surname><given-names>A</given-names></name><name name-style="western"><surname>Barratt</surname><given-names>MJ</given-names></name></person-group><article-title>Drug checking to detect fentanyl and new psychoactive substances</article-title><source>Curr Opin Psychiatry</source><year>2020</year><volume>33</volume><issue>4</issue><fpage>301</fpage><pub-id pub-id-type="doi">10.1097/YCO.0000000000000607</pub-id><pub-id pub-id-type="pmid">32187173</pub-id><pub-id pub-id-type="pmcid">PMC7255931</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Palamar JJ, Salomone A, Barratt MJ. Drug checking to detect fentanyl and new psychoactive substances. Curr Opin Psychiatry. 2020;33(4):301.<pub-id pub-id-type="pmid">32187173</pub-id><pub-id pub-id-type="doi">10.1097/YCO.0000000000000607</pub-id><pub-id pub-id-type="pmcid">PMC7255931</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dasgupta</surname><given-names>N</given-names></name></person-group><article-title>History and future of harm reduction in North Carolina: pragmatism and innovation</article-title><source>N C Med J.</source><year>2022</year><volume>83</volume><issue>4</issue><fpage>257</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">35817454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18043/ncm.83.4.257</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Dasgupta N. History and future of harm reduction in North Carolina: pragmatism and innovation. N C Med J. 2022;83(4):257&#8211;60.<pub-id pub-id-type="pmid">35817454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18043/ncm.83.4.257</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>AS</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>R</given-names></name><name name-style="western"><surname>Des Jarlais</surname><given-names>DC</given-names></name><name name-style="western"><surname>Aronson</surname><given-names>ID</given-names></name></person-group><article-title>Reasons people who use opioids do not accept or carry no-cost naloxone: qualitative interview study</article-title><source>JMIR Formative Res</source><year>2020</year><volume>4</volume><issue>12</issue><fpage>e22411</fpage><pub-id pub-id-type="doi">10.2196/22411</pub-id><pub-id pub-id-type="pmcid">PMC7787889</pub-id><pub-id pub-id-type="pmid">33355094</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Bennett AS, Freeman R, Des Jarlais DC, Aronson ID. Reasons people who use opioids do not accept or carry no-cost naloxone: qualitative interview study. JMIR Formative Res. 2020;4(12):e22411.<pub-id pub-id-type="doi">10.2196/22411</pub-id><pub-id pub-id-type="pmcid">PMC7787889</pub-id><pub-id pub-id-type="pmid">33355094</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casey</surname><given-names>MM</given-names></name><name name-style="western"><surname>Call</surname><given-names>KT</given-names></name><name name-style="western"><surname>Klingner</surname><given-names>JM</given-names></name></person-group><article-title>Are rural residents less likely to obtain recommended preventive healthcare services?</article-title><source>Am J Prev Med</source><year>2001</year><volume>21</volume><issue>3</issue><fpage>182</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S0749-3797(01)00349-X</pub-id><pub-id pub-id-type="pmid">11567838</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Casey MM, Call KT, Klingner JM. Are rural residents less likely to obtain recommended preventive healthcare services? Am J Prev Med. 2001;21(3):182&#8211;8.<pub-id pub-id-type="pmid">11567838</pub-id><pub-id pub-id-type="doi">10.1016/S0749-3797(01)00349-X</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Ricketts TC, Johnson-Webb KD, Randolph RK. Populations and places in rural America. Rural Health United States. 1999:7&#8211;24.</mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Schur CL, Franco SJ. Access to health care. Rural health in the United States. 1999:25&#8211;37.</mixed-citation></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laditka</surname><given-names>JN</given-names></name><name name-style="western"><surname>Laditka</surname><given-names>SB</given-names></name><name name-style="western"><surname>Probst</surname><given-names>JC</given-names></name></person-group><article-title>Health care access in rural areas: evidence that hospitalization for ambulatory care-sensitive conditions in the United States may increase with the level of rurality</article-title><source>Health Place.</source><year>2009</year><volume>15</volume><issue>3</issue><fpage>731</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.healthplace.2008.12.007</pub-id><pub-id pub-id-type="pmid">19211295</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Laditka JN, Laditka SB, Probst JC. Health care access in rural areas: evidence that hospitalization for ambulatory care-sensitive conditions in the United States may increase with the level of rurality. Health Place. 2009;15(3):731&#8211;40.<pub-id pub-id-type="pmid">19211295</pub-id><pub-id pub-id-type="doi">10.1016/j.healthplace.2008.12.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Meit M, Knudson A, Gilbert T, Yu AT-C, Tanenbaum E, Ormson E, et al. The 2014 update of the rural-urban chartbook. Bethesda, MD: Rural Health Reform Policy Research Center. 2014.</mixed-citation></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schranz</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>J</given-names></name><name name-style="western"><surname>Hurt</surname><given-names>CB</given-names></name><name name-style="western"><surname>Malvestutto</surname><given-names>C</given-names></name><name name-style="western"><surname>Miller</surname><given-names>WC</given-names></name></person-group><article-title>Challenges facing a rural opioid epidemic: treatment and prevention of HIV and hepatitis C</article-title><source>Curr HIV/Aids Rep</source><year>2018</year><volume>15</volume><issue>3</issue><fpage>245</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1007/s11904-018-0393-0</pub-id><pub-id pub-id-type="pmid">29796965</pub-id><pub-id pub-id-type="pmcid">PMC6085134</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Schranz AJ, Barrett J, Hurt CB, Malvestutto C, Miller WC. Challenges facing a rural opioid epidemic: treatment and prevention of HIV and hepatitis C. Curr HIV/Aids Rep. 2018;15(3):245&#8211;54.<pub-id pub-id-type="pmid">29796965</pub-id><pub-id pub-id-type="doi">10.1007/s11904-018-0393-0</pub-id><pub-id pub-id-type="pmcid">PMC6085134</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westergaard</surname><given-names>RP</given-names></name><name name-style="western"><surname>Stockman</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Hyland</surname><given-names>HA</given-names></name><name name-style="western"><surname>Guilfoyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Fangman</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Vergeront</surname><given-names>JM</given-names></name></person-group><article-title>Provider workforce assessment in a rural hepatitis C epidemic: implications for scale-up of antiviral therapy</article-title><source>J Prim Care Community Health.</source><year>2015</year><volume>6</volume><issue>3</issue><fpage>215</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1177/2150131914560229</pub-id><pub-id pub-id-type="pmid">25422260</pub-id><pub-id pub-id-type="pmcid">PMC4442083</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Westergaard RP, Stockman LJ, Hyland HA, Guilfoyle SM, Fangman JJ, Vergeront JM. Provider workforce assessment in a rural hepatitis C epidemic: implications for scale-up of antiviral therapy. J Prim Care Community Health. 2015;6(3):215&#8211;7.<pub-id pub-id-type="pmid">25422260</pub-id><pub-id pub-id-type="doi">10.1177/2150131914560229</pub-id><pub-id pub-id-type="pmcid">PMC4442083</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Browne</surname><given-names>T</given-names></name><name name-style="western"><surname>Priester</surname><given-names>MA</given-names></name><name name-style="western"><surname>Clone</surname><given-names>S</given-names></name><name name-style="western"><surname>Iachini</surname><given-names>A</given-names></name><name name-style="western"><surname>DeHart</surname><given-names>D</given-names></name><name name-style="western"><surname>Hock</surname><given-names>R</given-names></name></person-group><article-title>Barriers and facilitators to substance use treatment in the rural south: a qualitative study</article-title><source>J Rural Health</source><year>2016</year><volume>32</volume><issue>1</issue><fpage>92</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1111/jrh.12129</pub-id><pub-id pub-id-type="pmid">26184098</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Browne T, Priester MA, Clone S, Iachini A, DeHart D, Hock R. Barriers and facilitators to substance use treatment in the rural south: a qualitative study. J Rural Health. 2016;32(1):92&#8211;101.<pub-id pub-id-type="pmid">26184098</pub-id><pub-id pub-id-type="doi">10.1111/jrh.12129</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolinski</surname><given-names>R</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>K</given-names></name><name name-style="western"><surname>Zahnd</surname><given-names>WE</given-names></name><name name-style="western"><surname>Walters</surname><given-names>S</given-names></name><name name-style="western"><surname>McLuckie</surname><given-names>C</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>J</given-names></name><etal/></person-group><article-title>Social norms associated with nonmedical opioid use in rural communities: a systematic review</article-title><source>Transl Behav Med</source><year>2019</year><volume>9</volume><issue>6</issue><fpage>1224</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1093/tbm/ibz129</pub-id><pub-id pub-id-type="pmid">31504988</pub-id><pub-id pub-id-type="pmcid">PMC6875642</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Bolinski R, Ellis K, Zahnd WE, Walters S, McLuckie C, Schneider J, et al. Social norms associated with nonmedical opioid use in rural communities: a systematic review. Transl Behav Med. 2019;9(6):1224&#8211;32.<pub-id pub-id-type="pmid">31504988</pub-id><pub-id pub-id-type="doi">10.1093/tbm/ibz129</pub-id><pub-id pub-id-type="pmcid">PMC6875642</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellis</surname><given-names>K</given-names></name><name name-style="western"><surname>Walters</surname><given-names>S</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>S</given-names></name><name name-style="western"><surname>Ouellet</surname><given-names>L</given-names></name><name name-style="western"><surname>Ezell</surname><given-names>J</given-names></name><name name-style="western"><surname>Rosentel</surname><given-names>K</given-names></name><etal/></person-group><article-title>Breaching trust: a qualitative study of healthcare experiences of people who use drugs in a rural setting</article-title><source>Front Sociol</source><year>2020</year><volume>5</volume><fpage>593925</fpage><pub-id pub-id-type="doi">10.3389/fsoc.2020.593925</pub-id><pub-id pub-id-type="pmid">33869521</pub-id><pub-id pub-id-type="pmcid">PMC8022503</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Ellis K, Walters S, Friedman S, Ouellet L, Ezell J, Rosentel K, et al. Breaching trust: a qualitative study of healthcare experiences of people who use drugs in a rural setting. Front Sociol. 2020;5:593925. 10.3389/fsoc.2020.593925.<pub-id pub-id-type="pmid">33869521</pub-id><pub-id pub-id-type="doi">10.3389/fsoc.2020.593925</pub-id><pub-id pub-id-type="pmcid">PMC8022503</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ezell</surname><given-names>JM</given-names></name><name name-style="western"><surname>Walters</surname><given-names>S</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Bolinski</surname><given-names>R</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>WD</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>J</given-names></name><etal/></person-group><article-title>Stigmatize the use, not the user? Attitudes on opioid use, drug injection, treatment, and overdose prevention in rural communities</article-title><source>Soc Sci Med</source><year>2021</year><volume>268</volume><fpage>113470</fpage><pub-id pub-id-type="doi">10.1016/j.socscimed.2020.113470</pub-id><pub-id pub-id-type="pmid">33253992</pub-id><pub-id pub-id-type="pmcid">PMC7755701</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Ezell JM, Walters S, Friedman SR, Bolinski R, Jenkins WD, Schneider J, et al. Stigmatize the use, not the user? Attitudes on opioid use, drug injection, treatment, and overdose prevention in rural communities. Soc Sci Med. 2021;268:113470.<pub-id pub-id-type="pmid">33253992</pub-id><pub-id pub-id-type="doi">10.1016/j.socscimed.2020.113470</pub-id><pub-id pub-id-type="pmcid">PMC7755701</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">Walters SM, Frank D, Van Ham B, Jaiswal J, Muncan B, Earnshaw V, et al. PrEP care continuum engagement among persons who inject drugs: rural and urban differences in stigma and social infrastructure. AIDS Behav. 2021:1&#8211;13.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10461-021-03488-2</pub-id><pub-id pub-id-type="pmcid">PMC8501360</pub-id><pub-id pub-id-type="pmid">34626265</pub-id></mixed-citation></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagelhout</surname><given-names>GE</given-names></name><name name-style="western"><surname>Hummel</surname><given-names>K</given-names></name><name name-style="western"><surname>de Goeij</surname><given-names>MC</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>H</given-names></name><name name-style="western"><surname>Kaner</surname><given-names>E</given-names></name><name name-style="western"><surname>Lemmens</surname><given-names>P</given-names></name></person-group><article-title>How economic recessions and unemployment affect illegal drug use: a systematic realist literature review</article-title><source>Int J Drug Policy</source><year>2017</year><volume>44</volume><fpage>69</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2017.03.013</pub-id><pub-id pub-id-type="pmid">28454010</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Nagelhout GE, Hummel K, de Goeij MC, de Vries H, Kaner E, Lemmens P. How economic recessions and unemployment affect illegal drug use: a systematic realist literature review. Int J Drug Policy. 2017;44:69&#8211;83.<pub-id pub-id-type="pmid">28454010</pub-id><pub-id pub-id-type="doi">10.1016/j.drugpo.2017.03.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carpenter</surname><given-names>CS</given-names></name><name name-style="western"><surname>McClellan</surname><given-names>CB</given-names></name><name name-style="western"><surname>Rees</surname><given-names>DI</given-names></name></person-group><article-title>Economic conditions, illicit drug use, and substance use disorders in the United States</article-title><source>J Health Econ</source><year>2017</year><volume>52</volume><fpage>63</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.jhealeco.2016.12.009</pub-id><pub-id pub-id-type="pmid">28235697</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Carpenter CS, McClellan CB, Rees DI. Economic conditions, illicit drug use, and substance use disorders in the United States. J Health Econ. 2017;52:63&#8211;73.<pub-id pub-id-type="pmid">28235697</pub-id><pub-id pub-id-type="doi">10.1016/j.jhealeco.2016.12.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Rhodes</surname><given-names>T</given-names></name></person-group><source>Risk environments and drug harms: a social science for harm reduction approach</source><year>2009</year><publisher-loc>Amsterdam</publisher-loc><publisher-name>Elsevier</publisher-name><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugpo.2008.10.003</pub-id><pub-id pub-id-type="pmid">19147339</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="book">Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Amsterdam: Elsevier; 2009. p. 193&#8211;201.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugpo.2008.10.003</pub-id><pub-id pub-id-type="pmid">19147339</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawk</surname><given-names>M</given-names></name><name name-style="western"><surname>Coulter</surname><given-names>RW</given-names></name><name name-style="western"><surname>Egan</surname><given-names>JE</given-names></name><name name-style="western"><surname>Fisk</surname><given-names>S</given-names></name><name name-style="western"><surname>Reuel Friedman</surname><given-names>M</given-names></name><name name-style="western"><surname>Tula</surname><given-names>M</given-names></name><etal/></person-group><article-title>Harm reduction principles for healthcare settings</article-title><source>Harm Reduct J</source><year>2017</year><volume>14</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/s12954-017-0196-4</pub-id><pub-id pub-id-type="pmid">29065896</pub-id><pub-id pub-id-type="pmcid">PMC5655864</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Hawk M, Coulter RW, Egan JE, Fisk S, Reuel Friedman M, Tula M, et al. Harm reduction principles for healthcare settings. Harm Reduct J. 2017;14:1&#8211;9.<pub-id pub-id-type="pmid">29065896</pub-id><pub-id pub-id-type="doi">10.1186/s12954-017-0196-4</pub-id><pub-id pub-id-type="pmcid">PMC5655864</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Albers E. Harm reduction: contribution to a critical appraisal from the perspective of people who use drugs. Harm Reduct Subst Use High-Risk Behav Int Policy Pract. 2012:124&#8211;31.</mixed-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Coalition NHR. Principles of harm reduction. 2020.</mixed-citation></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>SR</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>W</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>D</given-names></name><name name-style="western"><surname>Touz&#233;</surname><given-names>G</given-names></name><name name-style="western"><surname>Rockwell</surname><given-names>R</given-names></name><name name-style="western"><surname>Des Jarlais</surname><given-names>DC</given-names></name><etal/></person-group><article-title>Harm reduction theory: users&#8217; culture, micro-social indigenous harm reduction, and the self-organization and outside-organizing of users&#8217; groups</article-title><source>Int J Drug Policy</source><year>2007</year><volume>18</volume><issue>2</issue><fpage>107</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2006.11.006</pub-id><pub-id pub-id-type="pmid">17689353</pub-id><pub-id pub-id-type="pmcid">PMC1945155</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Friedman SR, de Jong W, Rossi D, Touz&#233; G, Rockwell R, Des Jarlais DC, et al. Harm reduction theory: users&#8217; culture, micro-social indigenous harm reduction, and the self-organization and outside-organizing of users&#8217; groups. Int J Drug Policy. 2007;18(2):107&#8211;17.<pub-id pub-id-type="pmid">17689353</pub-id><pub-id pub-id-type="doi">10.1016/j.drugpo.2006.11.006</pub-id><pub-id pub-id-type="pmcid">PMC1945155</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>M</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>T</given-names></name></person-group><article-title>Methadone diversion as a protective strategy: the harm reduction potential of &#8216;generous constraints&#8217;</article-title><source>Int J Drug Policy</source><year>2013</year><volume>24</volume><issue>6</issue><fpage>e43</fpage><lpage>e50</lpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2012.10.003</pub-id><pub-id pub-id-type="pmid">23199896</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Harris M, Rhodes T. Methadone diversion as a protective strategy: the harm reduction potential of &#8216;generous constraints.&#8217; Int J Drug Policy. 2013;24(6):e43&#8211;50.<pub-id pub-id-type="pmid">23199896</pub-id><pub-id pub-id-type="doi">10.1016/j.drugpo.2012.10.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langendam</surname><given-names>MW</given-names></name><name name-style="western"><surname>van Brussel</surname><given-names>GH</given-names></name><name name-style="western"><surname>Coutinho</surname><given-names>RA</given-names></name><name name-style="western"><surname>Van Ameijden</surname><given-names>E</given-names></name></person-group><article-title>The impact of harm-reduction-based methadone treatment on mortality among heroin users</article-title><source>Am J Public Health</source><year>2001</year><volume>91</volume><issue>5</issue><fpage>774</fpage><pub-id pub-id-type="doi">10.2105/AJPH.91.5.774</pub-id><pub-id pub-id-type="pmid">11344886</pub-id><pub-id pub-id-type="pmcid">PMC1446673</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Langendam MW, van Brussel GH, Coutinho RA, Van Ameijden E. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Public Health. 2001;91(5):774.<pub-id pub-id-type="pmid">11344886</pub-id><pub-id pub-id-type="doi">10.2105/AJPH.91.5.774</pub-id><pub-id pub-id-type="pmcid">PMC1446673</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marlatt</surname><given-names>GA</given-names></name></person-group><article-title>Harm reduction: come as you are</article-title><source>Addict Behav.</source><year>1996</year><volume>21</volume><issue>6</issue><fpage>779</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/0306-4603(96)00042-1</pub-id><pub-id pub-id-type="pmid">8904943</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Marlatt GA. Harm reduction: come as you are. Addict Behav. 1996;21(6):779&#8211;88.<pub-id pub-id-type="pmid">8904943</pub-id><pub-id pub-id-type="doi">10.1016/0306-4603(96)00042-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parkin</surname><given-names>S</given-names></name><name name-style="western"><surname>Neale</surname><given-names>J</given-names></name><name name-style="western"><surname>Brown</surname><given-names>C</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>AN</given-names></name><name name-style="western"><surname>Castillo</surname><given-names>F</given-names></name><name name-style="western"><surname>Jones</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Opioid overdose reversals using naloxone in New York City by people who use opioids: Implications for public health and overdose harm reduction approaches from a qualitative study</article-title><source>Int J Drug Policy</source><year>2020</year><volume>79</volume><fpage>102751</fpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2020.102751</pub-id><pub-id pub-id-type="pmid">32304981</pub-id><pub-id pub-id-type="pmcid">PMC7572435</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Parkin S, Neale J, Brown C, Campbell AN, Castillo F, Jones JD, et al. Opioid overdose reversals using naloxone in New York City by people who use opioids: Implications for public health and overdose harm reduction approaches from a qualitative study. Int J Drug Policy. 2020;79:102751.<pub-id pub-id-type="pmid">32304981</pub-id><pub-id pub-id-type="doi">10.1016/j.drugpo.2020.102751</pub-id><pub-id pub-id-type="pmcid">PMC7572435</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vakharia</surname><given-names>SP</given-names></name><name name-style="western"><surname>Little</surname><given-names>J</given-names></name></person-group><article-title>Starting where the client is: harm reduction guidelines for clinical social work practice</article-title><source>Clin Soc Work J.</source><year>2017</year><volume>45</volume><issue>1</issue><fpage>65</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1007/s10615-016-0584-3</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Vakharia SP, Little J. Starting where the client is: harm reduction guidelines for clinical social work practice. Clin Soc Work J. 2017;45(1):65&#8211;76.<pub-id pub-id-type="doi">10.1007/s10615-016-0584-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giglio</surname><given-names>RE</given-names></name><name name-style="western"><surname>Mantha</surname><given-names>S</given-names></name><name name-style="western"><surname>Harocopos</surname><given-names>A</given-names></name><name name-style="western"><surname>Saha</surname><given-names>N</given-names></name><name name-style="western"><surname>Reilly</surname><given-names>J</given-names></name><name name-style="western"><surname>Cipriano</surname><given-names>C</given-names></name><etal/></person-group><article-title>The Nation&#8217;s first publicly recognized overdose prevention centers: lessons learned in New York City</article-title><source>J Urban Health</source><year>2023</year><volume>100</volume><issue>2</issue><fpage>245</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1007/s11524-023-00717-y</pub-id><pub-id pub-id-type="pmid">37016269</pub-id><pub-id pub-id-type="pmcid">PMC10072795</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Giglio RE, Mantha S, Harocopos A, Saha N, Reilly J, Cipriano C, et al. The Nation&#8217;s first publicly recognized overdose prevention centers: lessons learned in New York City. J Urban Health. 2023;100(2):245&#8211;54.<pub-id pub-id-type="pmid">37016269</pub-id><pub-id pub-id-type="doi">10.1007/s11524-023-00717-y</pub-id><pub-id pub-id-type="pmcid">PMC10072795</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marshall</surname><given-names>BD</given-names></name><name name-style="western"><surname>Milloy</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Wood</surname><given-names>E</given-names></name><name name-style="western"><surname>Montaner</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>T</given-names></name></person-group><article-title>Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study</article-title><source>The Lancet.</source><year>2011</year><volume>377</volume><issue>9775</issue><fpage>1429</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)62353-7</pub-id><pub-id pub-id-type="pmid">21497898</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America&#8217;s first medically supervised safer injecting facility: a retrospective population-based study. The Lancet. 2011;377(9775):1429&#8211;37.<pub-id pub-id-type="doi">10.1016/S0140-6736(10)62353-7</pub-id><pub-id pub-id-type="pmid">21497898</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Betsos</surname><given-names>A</given-names></name><name name-style="western"><surname>Valleriani</surname><given-names>J</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>J</given-names></name><name name-style="western"><surname>Bardwell</surname><given-names>G</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>T</given-names></name><name name-style="western"><surname>McNeil</surname><given-names>R</given-names></name></person-group><article-title>&#8220;I couldn't live with killing one of my friends or anybody&#8221;: a rapid ethnographic study of drug sellers&#8217; use of drug checking</article-title><source>Int J Drug Policy</source><year>2021</year><volume>87</volume><fpage>102845</fpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2020.102845</pub-id><pub-id pub-id-type="pmid">33246303</pub-id><pub-id pub-id-type="pmcid">PMC8020365</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Betsos A, Valleriani J, Boyd J, Bardwell G, Kerr T, McNeil R. &#8220;I couldn&#8217;t live with killing one of my friends or anybody&#8221;: a rapid ethnographic study of drug sellers&#8217; use of drug checking. Int J Drug Policy. 2021;87:102845.<pub-id pub-id-type="pmid">33246303</pub-id><pub-id pub-id-type="doi">10.1016/j.drugpo.2020.102845</pub-id><pub-id pub-id-type="pmcid">PMC8020365</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallace</surname><given-names>B</given-names></name><name name-style="western"><surname>Van Roode</surname><given-names>T</given-names></name><name name-style="western"><surname>Pagan</surname><given-names>F</given-names></name><name name-style="western"><surname>Hore</surname><given-names>D</given-names></name><name name-style="western"><surname>Pauly</surname><given-names>B</given-names></name></person-group><article-title>The potential impacts of community drug checking within the overdose crisis: qualitative study exploring the perspective of prospective service users</article-title><source>BMC Public Health.</source><year>2021</year><volume>21</volume><issue>1</issue><fpage>1156</fpage><pub-id pub-id-type="doi">10.1186/s12889-021-11243-4</pub-id><pub-id pub-id-type="pmid">34134698</pub-id><pub-id pub-id-type="pmcid">PMC8207696</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Wallace B, Van Roode T, Pagan F, Hore D, Pauly B. The potential impacts of community drug checking within the overdose crisis: qualitative study exploring the perspective of prospective service users. BMC Public Health. 2021;21(1):1156.<pub-id pub-id-type="pmid">34134698</pub-id><pub-id pub-id-type="doi">10.1186/s12889-021-11243-4</pub-id><pub-id pub-id-type="pmcid">PMC8207696</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muncan</surname><given-names>B</given-names></name><name name-style="western"><surname>Walters</surname><given-names>SM</given-names></name><name name-style="western"><surname>Ezell</surname><given-names>J</given-names></name><name name-style="western"><surname>Ompad</surname><given-names>DC</given-names></name></person-group><article-title>&#8220;They look at us like junkies&#8221;: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City</article-title><source>Harm Reduct J</source><year>2020</year><volume>17</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/s12954-020-00399-8</pub-id><pub-id pub-id-type="pmid">32736624</pub-id><pub-id pub-id-type="pmcid">PMC7393740</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Muncan B, Walters SM, Ezell J, Ompad DC. &#8220;They look at us like junkies&#8221;: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J. 2020;17(1):1&#8211;9.<pub-id pub-id-type="pmid">32736624</pub-id><pub-id pub-id-type="doi">10.1186/s12954-020-00399-8</pub-id><pub-id pub-id-type="pmcid">PMC7393740</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>CB</given-names></name></person-group><article-title>Harm reduction as anarchist practice: a user's guide to capitalism and addiction in North America</article-title><source>Crit Public Health</source><year>2012</year><volume>22</volume><issue>2</issue><fpage>209</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1080/09581596.2011.611487</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Smith CB. Harm reduction as anarchist practice: a user&#8217;s guide to capitalism and addiction in North America. Crit Public Health. 2012;22(2):209&#8211;21.<pub-id pub-id-type="doi">10.1080/09581596.2011.611487</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="other">Szott K. Expanding the mission of harm reduction: a public health population and its members&#8217; perspectives towards health. Critical approaches to harm reduction: conflict, institutionalization,(de-) politicization, and direct action, edited by Christopher BR Smith and Zack Marshall. 2016;169:84.</mixed-citation></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Williams</surname><given-names>LD</given-names></name><name name-style="western"><surname>Guarino</surname><given-names>H</given-names></name><name name-style="western"><surname>Mateu-Gelabert</surname><given-names>P</given-names></name><name name-style="western"><surname>Krawczyk</surname><given-names>N</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>L</given-names></name><etal/></person-group><article-title>The stigma system: how sociopolitical domination, scapegoating, and stigma shape public health</article-title><source>J Commun Psychol</source><year>2021</year><volume>50</volume><fpage>385</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1002/jcop.22581</pub-id><pub-id pub-id-type="pmcid">PMC8664901</pub-id><pub-id pub-id-type="pmid">34115390</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Friedman SR, Williams LD, Guarino H, Mateu-Gelabert P, Krawczyk N, Hamilton L, et al. The stigma system: how sociopolitical domination, scapegoating, and stigma shape public health. J Commun Psychol. 2021;50:385&#8211;408.<pub-id pub-id-type="doi">10.1002/jcop.22581</pub-id><pub-id pub-id-type="pmcid">PMC8664901</pub-id><pub-id pub-id-type="pmid">34115390</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tempalski</surname><given-names>B</given-names></name><name name-style="western"><surname>Flom</surname><given-names>PL</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Des Jarlais</surname><given-names>DC</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>JJ</given-names></name><name name-style="western"><surname>McKnight</surname><given-names>C</given-names></name><etal/></person-group><article-title>Social and political factors predicting the presence of syringe exchange programs in 96 US metropolitan areas</article-title><source>Am J Public Health</source><year>2007</year><volume>97</volume><issue>3</issue><fpage>437</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.2105/AJPH.2005.065961</pub-id><pub-id pub-id-type="pmid">17267732</pub-id><pub-id pub-id-type="pmcid">PMC1805016</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Tempalski B, Flom PL, Friedman SR, Des Jarlais DC, Friedman JJ, McKnight C, et al. Social and political factors predicting the presence of syringe exchange programs in 96 US metropolitan areas. Am J Public Health. 2007;97(3):437&#8211;47.<pub-id pub-id-type="pmid">17267732</pub-id><pub-id pub-id-type="doi">10.2105/AJPH.2005.065961</pub-id><pub-id pub-id-type="pmcid">PMC1805016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muncan</surname><given-names>B</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>AE</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>DC</given-names></name><name name-style="western"><surname>Frank</surname><given-names>D</given-names></name><name name-style="western"><surname>Ompad</surname><given-names>DC</given-names></name><name name-style="western"><surname>Walters</surname><given-names>SM</given-names></name></person-group><article-title>Acceptability and effectiveness of hepatitis C care at syringe service programs for people who inject drugs in New York City</article-title><source>Subst Use Misuse.</source><year>2021</year><volume>56</volume><issue>5</issue><fpage>728</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1080/10826084.2021.1892142</pub-id><pub-id pub-id-type="pmid">33682610</pub-id><pub-id pub-id-type="pmcid">PMC8514132</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Muncan B, Jordan AE, Perlman DC, Frank D, Ompad DC, Walters SM. Acceptability and effectiveness of hepatitis C care at syringe service programs for people who inject drugs in New York City. Subst Use Misuse. 2021;56(5):728&#8211;37.<pub-id pub-id-type="pmid">33682610</pub-id><pub-id pub-id-type="doi">10.1080/10826084.2021.1892142</pub-id><pub-id pub-id-type="pmcid">PMC8514132</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walters</surname><given-names>SM</given-names></name><name name-style="western"><surname>Felsher</surname><given-names>M</given-names></name><name name-style="western"><surname>Frank</surname><given-names>D</given-names></name><name name-style="western"><surname>Jaiswal</surname><given-names>J</given-names></name><name name-style="western"><surname>Townsend</surname><given-names>T</given-names></name><name name-style="western"><surname>Muncan</surname><given-names>B</given-names></name><etal/></person-group><article-title>I don&#8217;t believe a person has to die when trying to get high: overdose prevention and response strategies in rural Illinois</article-title><source>Int J Environ Res Public Health.</source><year>2023</year><volume>20</volume><issue>2</issue><fpage>1648</fpage><pub-id pub-id-type="doi">10.3390/ijerph20021648</pub-id><pub-id pub-id-type="pmid">36674402</pub-id><pub-id pub-id-type="pmcid">PMC9864395</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Walters SM, Felsher M, Frank D, Jaiswal J, Townsend T, Muncan B, et al. I don&#8217;t believe a person has to die when trying to get high: overdose prevention and response strategies in rural Illinois. Int J Environ Res Public Health. 2023;20(2):1648.<pub-id pub-id-type="pmid">36674402</pub-id><pub-id pub-id-type="doi">10.3390/ijerph20021648</pub-id><pub-id pub-id-type="pmcid">PMC9864395</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antoniou</surname><given-names>T</given-names></name><name name-style="western"><surname>Pritlove</surname><given-names>C</given-names></name><name name-style="western"><surname>Shearer</surname><given-names>D</given-names></name><name name-style="western"><surname>Martins</surname><given-names>D</given-names></name><name name-style="western"><surname>Tadrous</surname><given-names>M</given-names></name><name name-style="western"><surname>Munro</surname><given-names>C</given-names></name><etal/></person-group><article-title>A qualitative study of a publicly funded pharmacy-dispensed naloxone program</article-title><source>Int J Drug Policy</source><year>2021</year><volume>92</volume><fpage>103146</fpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2021.103146</pub-id><pub-id pub-id-type="pmid">33568317</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Antoniou T, Pritlove C, Shearer D, Martins D, Tadrous M, Munro C, et al. A qualitative study of a publicly funded pharmacy-dispensed naloxone program. Int J Drug Policy. 2021;92:103146.<pub-id pub-id-type="pmid">33568317</pub-id><pub-id pub-id-type="doi">10.1016/j.drugpo.2021.103146</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>AS</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>L</given-names></name></person-group><article-title>Naloxone's role in the national opioid crisis&#8212;past struggles, current efforts, and future opportunities</article-title><source>Transl Res</source><year>2021</year><volume>234</volume><fpage>43</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2021.03.001</pub-id><pub-id pub-id-type="pmid">33684591</pub-id><pub-id pub-id-type="pmcid">PMC8327685</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Bennett AS, Elliott L. Naloxone&#8217;s role in the national opioid crisis&#8212;past struggles, current efforts, and future opportunities. Transl Res. 2021;234:43&#8211;57.<pub-id pub-id-type="pmid">33684591</pub-id><pub-id pub-id-type="doi">10.1016/j.trsl.2021.03.001</pub-id><pub-id pub-id-type="pmcid">PMC8327685</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jenkins</surname><given-names>RA</given-names></name><name name-style="western"><surname>Whitney</surname><given-names>BM</given-names></name><name name-style="western"><surname>Nance</surname><given-names>RM</given-names></name><name name-style="western"><surname>Allen</surname><given-names>TM</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>HLF</given-names></name><name name-style="western"><surname>Feinberg</surname><given-names>J</given-names></name><etal/></person-group><article-title>The rural opioid initiative consortium description: providing evidence to understand the fourth wave of the opioid crisis</article-title><source>Addict Sci Clin Pract</source><year>2022</year><volume>17</volume><issue>1</issue><fpage>38</fpage><pub-id pub-id-type="doi">10.1186/s13722-022-00322-5</pub-id><pub-id pub-id-type="pmid">35883197</pub-id><pub-id pub-id-type="pmcid">PMC9321271</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Jenkins RA, Whitney BM, Nance RM, Allen TM, Cooper HLF, Feinberg J, et al. The rural opioid initiative consortium description: providing evidence to understand the fourth wave of the opioid crisis. Addict Sci Clin Pract. 2022;17(1):38.<pub-id pub-id-type="pmid">35883197</pub-id><pub-id pub-id-type="doi">10.1186/s13722-022-00322-5</pub-id><pub-id pub-id-type="pmcid">PMC9321271</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Handel</surname><given-names>MM</given-names></name><name name-style="western"><surname>Rose</surname><given-names>CE</given-names></name><name name-style="western"><surname>Hallisey</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Kolling</surname><given-names>JL</given-names></name><name name-style="western"><surname>Zibbell</surname><given-names>JE</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>B</given-names></name><etal/></person-group><article-title>County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States</article-title><source>J Acquir Immune Defic Syndr.</source><year>2016</year><volume>73</volume><issue>3</issue><fpage>323</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000001098</pub-id><pub-id pub-id-type="pmid">27763996</pub-id><pub-id pub-id-type="pmcid">PMC5479631</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Van Handel MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, Lewis B, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr. 2016;73(3):323&#8211;31.<pub-id pub-id-type="pmid">27763996</pub-id><pub-id pub-id-type="doi">10.1097/QAI.0000000000001098</pub-id><pub-id pub-id-type="pmcid">PMC5479631</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>N</given-names></name><name name-style="western"><surname>Kariisa</surname><given-names>M</given-names></name><name name-style="western"><surname>Seth</surname><given-names>P</given-names></name><name name-style="western"><surname>Smith</surname><given-names>H</given-names></name><name name-style="western"><surname>Davis</surname><given-names>NL</given-names></name></person-group><article-title>Drug and opioid-involved overdose deaths - United States, 2017&#8211;2018</article-title><source>MMWR Morb Mortal Wkly Rep.</source><year>2020</year><volume>69</volume><issue>11</issue><fpage>290</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6911a4</pub-id><pub-id pub-id-type="pmid">32191688</pub-id><pub-id pub-id-type="pmcid">PMC7739981</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Wilson N, Kariisa M, Seth P, Smith H, Davis NL. Drug and opioid-involved overdose deaths - United States, 2017&#8211;2018. MMWR Morb Mortal Wkly Rep. 2020;69(11):290&#8211;7.<pub-id pub-id-type="pmid">32191688</pub-id><pub-id pub-id-type="doi">10.15585/mmwr.mm6911a4</pub-id><pub-id pub-id-type="pmcid">PMC7739981</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenblatt</surname><given-names>RA</given-names></name><name name-style="western"><surname>Andrilla</surname><given-names>CH</given-names></name><name name-style="western"><surname>Catlin</surname><given-names>M</given-names></name><name name-style="western"><surname>Larson</surname><given-names>EH</given-names></name></person-group><article-title>Geographic and specialty distribution of US physicians trained to treat opioid use disorder</article-title><source>Ann Fam Med.</source><year>2015</year><volume>13</volume><issue>1</issue><fpage>23</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1370/afm.1735</pub-id><pub-id pub-id-type="pmid">25583888</pub-id><pub-id pub-id-type="pmcid">PMC4291261</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Rosenblatt RA, Andrilla CH, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23&#8211;6.<pub-id pub-id-type="pmid">25583888</pub-id><pub-id pub-id-type="doi">10.1370/afm.1735</pub-id><pub-id pub-id-type="pmcid">PMC4291261</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ballard</surname><given-names>AM</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>HLF</given-names></name></person-group><article-title>Novel recruitment methods for research among young adults in rural areas who use opioids: cookouts, coupons, and community-based staff</article-title><source>Public Health Rep</source><year>2020</year><volume>135</volume><issue>6</issue><fpage>746</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1177/0033354920954796</pub-id><pub-id pub-id-type="pmid">32933438</pub-id><pub-id pub-id-type="pmcid">PMC7649997</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Young AM, Ballard AM, Cooper HLF. Novel recruitment methods for research among young adults in rural areas who use opioids: cookouts, coupons, and community-based staff. Public Health Rep. 2020;135(6):746&#8211;55.<pub-id pub-id-type="pmid">32933438</pub-id><pub-id pub-id-type="doi">10.1177/0033354920954796</pub-id><pub-id pub-id-type="pmcid">PMC7649997</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><mixed-citation publication-type="other">Charmaz K, Belgrave LL. Grounded theory. The Blackwell encyclopedia of sociology. 2007.</mixed-citation></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>V</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>V</given-names></name></person-group><article-title>Using thematic analysis in psychology</article-title><source>Qual Res Psychol</source><year>2006</year><volume>3</volume><issue>2</issue><fpage>77</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1191/1478088706qp063oa</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77&#8211;101.<pub-id pub-id-type="doi">10.1191/1478088706qp063oa</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>CM</given-names></name><name name-style="western"><surname>Bekheet</surname><given-names>F</given-names></name><name name-style="western"><surname>Park</surname><given-names>JN</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>GC</given-names></name></person-group><article-title>The evolving overdose epidemic: synthetic opioids and rising stimulant-related harms</article-title><source>Epidemiol Rev</source><year>2020</year><volume>42</volume><issue>1</issue><fpage>154</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1093/epirev/mxaa011</pub-id><pub-id pub-id-type="pmid">33511987</pub-id><pub-id pub-id-type="pmcid">PMC9200066</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Jones CM, Bekheet F, Park JN, Alexander GC. The evolving overdose epidemic: synthetic opioids and rising stimulant-related harms. Epidemiol Rev. 2020;42(1):154&#8211;66.<pub-id pub-id-type="pmid">33511987</pub-id><pub-id pub-id-type="doi">10.1093/epirev/mxaa011</pub-id><pub-id pub-id-type="pmcid">PMC9200066</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciccarone</surname><given-names>D</given-names></name></person-group><article-title>The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis</article-title><source>Curr Opin Psychiatry.</source><year>2021</year><volume>34</volume><issue>4</issue><fpage>344</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1097/YCO.0000000000000717</pub-id><pub-id pub-id-type="pmid">33965972</pub-id><pub-id pub-id-type="pmcid">PMC8154745</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344&#8211;50.<pub-id pub-id-type="pmid">33965972</pub-id><pub-id pub-id-type="doi">10.1097/YCO.0000000000000717</pub-id><pub-id pub-id-type="pmcid">PMC8154745</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korthuis</surname><given-names>PT</given-names></name><name name-style="western"><surname>Cook</surname><given-names>RR</given-names></name><name name-style="western"><surname>Foot</surname><given-names>CA</given-names></name><name name-style="western"><surname>Leichtling</surname><given-names>G</given-names></name><name name-style="western"><surname>Tsui</surname><given-names>JI</given-names></name><name name-style="western"><surname>Stopka</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Association of methamphetamine and opioid use with nonfatal overdose in rural communities</article-title><source>JAMA Netw Open.</source><year>2022</year><volume>5</volume><issue>8</issue><fpage>e2226544</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.26544</pub-id><pub-id pub-id-type="pmid">35969400</pub-id><pub-id pub-id-type="pmcid">PMC9379740</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Korthuis PT, Cook RR, Foot CA, Leichtling G, Tsui JI, Stopka TJ, et al. Association of methamphetamine and opioid use with nonfatal overdose in rural communities. JAMA Netw Open. 2022;5(8):e2226544.<pub-id pub-id-type="pmid">35969400</pub-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.26544</pub-id><pub-id pub-id-type="pmcid">PMC9379740</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>J</given-names></name><name name-style="western"><surname>Tanz</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Gladden</surname><given-names>RM</given-names></name><name name-style="western"><surname>Davis</surname><given-names>NL</given-names></name><name name-style="western"><surname>Bitting</surname><given-names>J</given-names></name></person-group><article-title>Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls&#8212;United States, 2019&#8211;2020</article-title><source>Morb Mortal Wkl Rep</source><year>2021</year><volume>70</volume><issue>50</issue><fpage>1740</fpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7050e3</pub-id><pub-id pub-id-type="pmcid">PMC8675656</pub-id><pub-id pub-id-type="pmid">34914673</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">O&#8217;Donnell J, Tanz LJ, Gladden RM, Davis NL, Bitting J. Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls&#8212;United States, 2019&#8211;2020. Morb Mortal Wkl Rep. 2021;70(50):1740.<pub-id pub-id-type="doi">10.15585/mmwr.mm7050e3</pub-id><pub-id pub-id-type="pmcid">PMC8675656</pub-id><pub-id pub-id-type="pmid">34914673</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Twillman</surname><given-names>RK</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>E</given-names></name><name name-style="western"><surname>LaRue</surname><given-names>L</given-names></name><name name-style="western"><surname>Guevara</surname><given-names>MG</given-names></name><name name-style="western"><surname>Whitley</surname><given-names>P</given-names></name><name name-style="western"><surname>Huskey</surname><given-names>A</given-names></name></person-group><article-title>Evaluation of trends of near-real-time urine drug test results for methamphetamine, cocaine, heroin, and fentanyl</article-title><source>JAMA Netw Open.</source><year>2020</year><volume>3</volume><issue>1</issue><fpage>e1918514</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.18514</pub-id><pub-id pub-id-type="pmid">31899527</pub-id><pub-id pub-id-type="pmcid">PMC6991312</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Twillman RK, Dawson E, LaRue L, Guevara MG, Whitley P, Huskey A. Evaluation of trends of near-real-time urine drug test results for methamphetamine, cocaine, heroin, and fentanyl. JAMA Netw Open. 2020;3(1):e1918514.<pub-id pub-id-type="pmid">31899527</pub-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.18514</pub-id><pub-id pub-id-type="pmcid">PMC6991312</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korthuis</surname><given-names>PT</given-names></name><name name-style="western"><surname>Cook</surname><given-names>RR</given-names></name><name name-style="western"><surname>Foot</surname><given-names>CA</given-names></name><name name-style="western"><surname>Leichtling</surname><given-names>G</given-names></name><name name-style="western"><surname>Tsui</surname><given-names>JI</given-names></name><name name-style="western"><surname>Stopka</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Association of methamphetamine and opioid use with nonfatal overdose in rural communities</article-title><source>JAMA Netw Open</source><year>2022</year><volume>5</volume><issue>8</issue><fpage>e2226544</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.26544</pub-id><pub-id pub-id-type="pmid">35969400</pub-id><pub-id pub-id-type="pmcid">PMC9379740</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Korthuis PT, Cook RR, Foot CA, Leichtling G, Tsui JI, Stopka TJ, et al. Association of methamphetamine and opioid use with nonfatal overdose in rural communities. JAMA Netw Open. 2022;5(8):e2226544.<pub-id pub-id-type="pmid">35969400</pub-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.26544</pub-id><pub-id pub-id-type="pmcid">PMC9379740</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciccarone</surname><given-names>D</given-names></name><name name-style="western"><surname>Ondocsin</surname><given-names>J</given-names></name><name name-style="western"><surname>Mars</surname><given-names>SG</given-names></name></person-group><article-title>Heroin uncertainties: Exploring users&#8217; perceptions of fentanyl-adulterated and -substituted &#8216;heroin&#8217;</article-title><source>Int J Drug Policy</source><year>2017</year><volume>46</volume><fpage>146</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2017.06.004</pub-id><pub-id pub-id-type="pmid">28735775</pub-id><pub-id pub-id-type="pmcid">PMC5577861</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Ciccarone D, Ondocsin J, Mars SG. Heroin uncertainties: Exploring users&#8217; perceptions of fentanyl-adulterated and -substituted &#8216;heroin.&#8217; Int J Drug Policy. 2017;46:146&#8211;55.<pub-id pub-id-type="pmid">28735775</pub-id><pub-id pub-id-type="doi">10.1016/j.drugpo.2017.06.004</pub-id><pub-id pub-id-type="pmcid">PMC5577861</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mars</surname><given-names>SG</given-names></name><name name-style="western"><surname>Ondocsin</surname><given-names>J</given-names></name><name name-style="western"><surname>Ciccarone</surname><given-names>D</given-names></name></person-group><article-title>Sold as heroin: perceptions and use of an evolving drug in Baltimore, MD</article-title><source>J Psychoact .</source><year>2018</year><volume>50</volume><issue>2</issue><fpage>167</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1080/02791072.2017.1394508</pub-id><pub-id pub-id-type="pmcid">PMC6114137</pub-id><pub-id pub-id-type="pmid">29211971</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Mars SG, Ondocsin J, Ciccarone D. Sold as heroin: perceptions and use of an evolving drug in Baltimore, MD. J Psychoact . 2018;50(2):167&#8211;76.<pub-id pub-id-type="doi">10.1080/02791072.2017.1394508</pub-id><pub-id pub-id-type="pmcid">PMC6114137</pub-id><pub-id pub-id-type="pmid">29211971</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walters</surname><given-names>SM</given-names></name><name name-style="western"><surname>Coston</surname><given-names>B</given-names></name><name name-style="western"><surname>Neaigus</surname><given-names>A</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>AV</given-names></name><name name-style="western"><surname>Starbuck</surname><given-names>L</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>V</given-names></name><etal/></person-group><article-title>The role of syringe exchange programs and sexual identity in awareness of pre-exposure prophylaxis (PrEP) for male persons who inject drugs</article-title><source>Int J Drug Policy.</source><year>2020</year><volume>77</volume><fpage>102671</fpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2020.102671</pub-id><pub-id pub-id-type="pmid">32092665</pub-id><pub-id pub-id-type="pmcid">PMC7245771</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Walters SM, Coston B, Neaigus A, Rivera AV, Starbuck L, Ramirez V, et al. The role of syringe exchange programs and sexual identity in awareness of pre-exposure prophylaxis (PrEP) for male persons who inject drugs. Int J Drug Policy. 2020;77:102671.<pub-id pub-id-type="pmid">32092665</pub-id><pub-id pub-id-type="doi">10.1016/j.drugpo.2020.102671</pub-id><pub-id pub-id-type="pmcid">PMC7245771</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walters</surname><given-names>SM</given-names></name><name name-style="western"><surname>Reilly</surname><given-names>KH</given-names></name><name name-style="western"><surname>Neaigus</surname><given-names>A</given-names></name><name name-style="western"><surname>Braunstein</surname><given-names>S</given-names></name></person-group><article-title>Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention</article-title><source>Harm Reduct J</source><year>2017</year><volume>14</volume><issue>1</issue><fpage>40</fpage><pub-id pub-id-type="doi">10.1186/s12954-017-0166-x</pub-id><pub-id pub-id-type="pmid">28662716</pub-id><pub-id pub-id-type="pmcid">PMC5492910</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Walters SM, Reilly KH, Neaigus A, Braunstein S. Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. Harm Reduct J. 2017;14(1):40.<pub-id pub-id-type="pmid">28662716</pub-id><pub-id pub-id-type="doi">10.1186/s12954-017-0166-x</pub-id><pub-id pub-id-type="pmcid">PMC5492910</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>AS</given-names></name><name name-style="western"><surname>Golub</surname><given-names>A</given-names></name><name name-style="western"><surname>Dunlap</surname><given-names>E</given-names></name></person-group><article-title>Drug market reconstitution after Hurricane Katrina: lessons for local drug abuse control initiatives</article-title><source>Just Res Policy</source><year>2011</year><volume>13</volume><issue>1</issue><fpage>23</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.3818/JRP.13.1.2011.23</pub-id><pub-id pub-id-type="pmcid">PMC3349334</pub-id><pub-id pub-id-type="pmid">22582027</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Bennett AS, Golub A, Dunlap E. Drug market reconstitution after Hurricane Katrina: lessons for local drug abuse control initiatives. Just Res Policy. 2011;13(1):23&#8211;44.<pub-id pub-id-type="doi">10.3818/JRP.13.1.2011.23</pub-id><pub-id pub-id-type="pmcid">PMC3349334</pub-id><pub-id pub-id-type="pmid">22582027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agley</surname><given-names>J</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>C</given-names></name><name name-style="western"><surname>Adams</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hulvershorn</surname><given-names>L</given-names></name></person-group><article-title>Provider engagement in Indiana&#8217;s opioid use disorder ECHO programme: there is a will but not always a way</article-title><source>BMJ Open Qual</source><year>2021</year><volume>10</volume><issue>2</issue><fpage>e001170</fpage><pub-id pub-id-type="doi">10.1136/bmjoq-2020-001170</pub-id><pub-id pub-id-type="pmid">33849905</pub-id><pub-id pub-id-type="pmcid">PMC8051380</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Agley J, Henderson C, Adams Z, Hulvershorn L. Provider engagement in Indiana&#8217;s opioid use disorder ECHO programme: there is a will but not always a way. BMJ Open Qual. 2021;10(2):e001170.<pub-id pub-id-type="pmid">33849905</pub-id><pub-id pub-id-type="doi">10.1136/bmjoq-2020-001170</pub-id><pub-id pub-id-type="pmcid">PMC8051380</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dasgupta</surname><given-names>N</given-names></name></person-group><article-title>We can't arrest our way out of overdose: the drug bust paradox</article-title><source>Am J Public Health</source><year>2023</year><volume>113</volume><issue>7</issue><fpage>708</fpage><pub-id pub-id-type="doi">10.2105/AJPH.2023.307329</pub-id><pub-id pub-id-type="pmid">37285571</pub-id><pub-id pub-id-type="pmcid">PMC10262240</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Dasgupta N. We can&#8217;t arrest our way out of overdose: the drug bust paradox. Am J Public Health. 2023;113(7):708.<pub-id pub-id-type="pmid">37285571</pub-id><pub-id pub-id-type="doi">10.2105/AJPH.2023.307329</pub-id><pub-id pub-id-type="pmcid">PMC10262240</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ray</surname><given-names>B</given-names></name><name name-style="western"><surname>Korzeniewski</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Mohler</surname><given-names>G</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Del Pozo</surname><given-names>B</given-names></name><name name-style="western"><surname>Victor</surname><given-names>G</given-names></name><etal/></person-group><article-title>Spatiotemporal analysis exploring the effect of law enforcement drug market disruptions on overdose, Indianapolis, Indiana, 2020&#8211;2021</article-title><source>Am J Public Health.</source><year>2023</year><volume>113</volume><issue>7</issue><fpage>750</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.2105/AJPH.2023.307291</pub-id><pub-id pub-id-type="pmid">37285563</pub-id><pub-id pub-id-type="pmcid">PMC10262257</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Ray B, Korzeniewski SJ, Mohler G, Carroll JJ, Del Pozo B, Victor G, et al. Spatiotemporal analysis exploring the effect of law enforcement drug market disruptions on overdose, Indianapolis, Indiana, 2020&#8211;2021. Am J Public Health. 2023;113(7):750&#8211;8.<pub-id pub-id-type="pmid">37285563</pub-id><pub-id pub-id-type="doi">10.2105/AJPH.2023.307291</pub-id><pub-id pub-id-type="pmcid">PMC10262257</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerstel</surname><given-names>N</given-names></name><name name-style="western"><surname>Bogard</surname><given-names>CJ</given-names></name><name name-style="western"><surname>McConnell</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>M</given-names></name></person-group><article-title>The therapeutic incarceration of homeless families</article-title><source>Soc Serv Rev</source><year>1996</year><volume>70</volume><issue>4</issue><fpage>543</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1086/604215</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Gerstel N, Bogard CJ, McConnell JJ, Schwartz M. The therapeutic incarceration of homeless families. Soc Serv Rev. 1996;70(4):543&#8211;72.<pub-id pub-id-type="doi">10.1086/604215</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santelices</surname><given-names>C</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>A</given-names></name><name name-style="western"><surname>Boulad</surname><given-names>M</given-names></name><name name-style="western"><surname>Stopka</surname><given-names>TJ</given-names></name></person-group><article-title>Evaluating technologies to identify fentanyl and adulterants in street drug paraphernalia: qualitative perspectives of service providers and their clientele</article-title><source>Subst Use Misuse.</source><year>2023</year><volume>58</volume><issue>12</issue><fpage>1528</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1080/10826084.2023.2231067</pub-id><pub-id pub-id-type="pmid">37424449</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Santelices C, Matsumoto A, Boulad M, Stopka TJ. Evaluating technologies to identify fentanyl and adulterants in street drug paraphernalia: qualitative perspectives of service providers and their clientele. Subst Use Misuse. 2023;58(12):1528&#8211;35.<pub-id pub-id-type="pmid">37424449</pub-id><pub-id pub-id-type="doi">10.1080/10826084.2023.2231067</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><mixed-citation publication-type="other">Allen ST, O&#8217;Rourke A, White RH, Sherman SG, Grieb SM. Perspectives on fentanyl test strip use among people who inject drugs in rural appalachia. Subst Use Misuse. 2020:1&#8211;7.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10826084.2020.1753773</pub-id><pub-id pub-id-type="pmid">32336188</pub-id></mixed-citation></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKnight</surname><given-names>C</given-names></name><name name-style="western"><surname>Des Jarlais</surname><given-names>DC</given-names></name></person-group><article-title>Being &#8220;hooked up&#8221; during a sharp increase in the availability of illicitly manufactured fentanyl: Adaptations of drug using practices among people who use drugs (PWUD) in New York City</article-title><source>Int J Drug Policy</source><year>2018</year><volume>60</volume><fpage>82</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2018.08.004</pub-id><pub-id pub-id-type="pmid">30176422</pub-id><pub-id pub-id-type="pmcid">PMC6457118</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">McKnight C, Des Jarlais DC. Being &#8220;hooked up&#8221; during a sharp increase in the availability of illicitly manufactured fentanyl: Adaptations of drug using practices among people who use drugs (PWUD) in New York City. Int J Drug Policy. 2018;60:82&#8211;8.<pub-id pub-id-type="pmid">30176422</pub-id><pub-id pub-id-type="doi">10.1016/j.drugpo.2018.08.004</pub-id><pub-id pub-id-type="pmcid">PMC6457118</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peiper</surname><given-names>NC</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>SD</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>LB</given-names></name><name name-style="western"><surname>Ciccarone</surname><given-names>D</given-names></name><name name-style="western"><surname>Kral</surname><given-names>AH</given-names></name><name name-style="western"><surname>Zibbell</surname><given-names>JE</given-names></name></person-group><article-title>Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the Southeastern United States</article-title><source>Int J Drug Policy</source><year>2019</year><volume>63</volume><fpage>122</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2018.08.007</pub-id><pub-id pub-id-type="pmid">30292493</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the Southeastern United States. Int J Drug Policy. 2019;63:122&#8211;8.<pub-id pub-id-type="pmid">30292493</pub-id><pub-id pub-id-type="doi">10.1016/j.drugpo.2018.08.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayer</surname><given-names>S</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>J</given-names></name><name name-style="western"><surname>Collins</surname><given-names>A</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>MC</given-names></name><name name-style="western"><surname>Fairbairn</surname><given-names>N</given-names></name><name name-style="western"><surname>McNeil</surname><given-names>R</given-names></name></person-group><article-title>Characterizing fentanyl-related overdoses and implications for overdose response: findings from a rapid ethnographic study in Vancouver, Canada</article-title><source>Drug Alcohol Depend</source><year>2018</year><volume>193</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.09.006</pub-id><pub-id pub-id-type="pmid">30343236</pub-id><pub-id pub-id-type="pmcid">PMC6447427</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Mayer S, Boyd J, Collins A, Kennedy MC, Fairbairn N, McNeil R. Characterizing fentanyl-related overdoses and implications for overdose response: findings from a rapid ethnographic study in Vancouver, Canada. Drug Alcohol Depend. 2018;193:69&#8211;74.<pub-id pub-id-type="pmid">30343236</pub-id><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.09.006</pub-id><pub-id pub-id-type="pmcid">PMC6447427</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perri</surname><given-names>M</given-names></name><name name-style="western"><surname>Kaminski</surname><given-names>N</given-names></name><name name-style="western"><surname>Bonn</surname><given-names>M</given-names></name><name name-style="western"><surname>Kolla</surname><given-names>G</given-names></name><name name-style="western"><surname>Guta</surname><given-names>A</given-names></name><name name-style="western"><surname>Bayoumi</surname><given-names>AM</given-names></name><etal/></person-group><article-title>A qualitative study on overdose response in the era of COVID-19 and beyond: how to spot someone so they never have to use alone</article-title><source>Harm Reduct J</source><year>2021</year><volume>18</volume><issue>1</issue><fpage>85</fpage><pub-id pub-id-type="doi">10.1186/s12954-021-00530-3</pub-id><pub-id pub-id-type="pmid">34353323</pub-id><pub-id pub-id-type="pmcid">PMC8339679</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Perri M, Kaminski N, Bonn M, Kolla G, Guta A, Bayoumi AM, et al. A qualitative study on overdose response in the era of COVID-19 and beyond: how to spot someone so they never have to use alone. Harm Reduct J. 2021;18(1):85.<pub-id pub-id-type="pmid">34353323</pub-id><pub-id pub-id-type="doi">10.1186/s12954-021-00530-3</pub-id><pub-id pub-id-type="pmcid">PMC8339679</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pustz</surname><given-names>J</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>S</given-names></name><name name-style="western"><surname>Larochelle</surname><given-names>MR</given-names></name><name name-style="western"><surname>Walley</surname><given-names>AY</given-names></name><name name-style="western"><surname>Stopka</surname><given-names>TJ</given-names></name></person-group><article-title>Relationships between places of residence, injury, and death: Spatial and statistical analysis of fatal opioid overdoses across Massachusetts</article-title><source>Spat Spatiotemporal Epidemiol.</source><year>2022</year><volume>43</volume><fpage>100541</fpage><pub-id pub-id-type="doi">10.1016/j.sste.2022.100541</pub-id><pub-id pub-id-type="pmid">36460457</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Pustz J, Srinivasan S, Larochelle MR, Walley AY, Stopka TJ. Relationships between places of residence, injury, and death: Spatial and statistical analysis of fatal opioid overdoses across Massachusetts. Spat Spatiotemporal Epidemiol. 2022;43:100541.<pub-id pub-id-type="pmid">36460457</pub-id><pub-id pub-id-type="doi">10.1016/j.sste.2022.100541</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ritchie</surname><given-names>K</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>SM</given-names></name></person-group><article-title>Determining the feasibility for an overdose prevention line to support substance users who use alone</article-title><source>Harm Reduction Journal.</source><year>2022</year><volume>19</volume><issue>1</issue><fpage>92</fpage><pub-id pub-id-type="doi">10.1186/s12954-022-00670-0</pub-id><pub-id pub-id-type="pmid">35986328</pub-id><pub-id pub-id-type="pmcid">PMC9389809</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Ritchie K, Ghosh SM. Determining the feasibility for an overdose prevention line to support substance users who use alone. Harm Reduction Journal. 2022;19(1):92.<pub-id pub-id-type="pmid">35986328</pub-id><pub-id pub-id-type="doi">10.1186/s12954-022-00670-0</pub-id><pub-id pub-id-type="pmcid">PMC9389809</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>MK</given-names></name><name name-style="western"><surname>Roth</surname><given-names>AM</given-names></name><name name-style="western"><surname>Tabb</surname><given-names>LP</given-names></name><name name-style="western"><surname>Groves</surname><given-names>AK</given-names></name><name name-style="western"><surname>Lankenau</surname><given-names>SE</given-names></name></person-group><article-title>&#8220;I probably got a minute&#8221;: perceptions of fentanyl test strip use among people who use stimulants</article-title><source>Int J Drug Policy</source><year>2021</year><volume>92</volume><fpage>103147</fpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2021.103147</pub-id><pub-id pub-id-type="pmid">33583679</pub-id><pub-id pub-id-type="pmcid">PMC8217094</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Reed MK, Roth AM, Tabb LP, Groves AK, Lankenau SE. &#8220;I probably got a minute&#8221;: perceptions of fentanyl test strip use among people who use stimulants. Int J Drug Policy. 2021;92:103147.<pub-id pub-id-type="pmid">33583679</pub-id><pub-id pub-id-type="doi">10.1016/j.drugpo.2021.103147</pub-id><pub-id pub-id-type="pmcid">PMC8217094</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliva</surname><given-names>EM</given-names></name><name name-style="western"><surname>Christopher</surname><given-names>MLD</given-names></name><name name-style="western"><surname>Wells</surname><given-names>D</given-names></name><name name-style="western"><surname>Bounthavong</surname><given-names>M</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>M</given-names></name><name name-style="western"><surname>Himstreet</surname><given-names>J</given-names></name><etal/></person-group><article-title>Opioid overdose education and naloxone distribution: Development of the Veterans Health Administration&#8217;s national program</article-title><source>J Am Pharm Assoc.</source><year>2017</year><volume>57</volume><issue>2</issue><fpage>S168</fpage><lpage>S79</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2017.01.022</pub-id><pub-id pub-id-type="pmid">28292502</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Oliva EM, Christopher MLD, Wells D, Bounthavong M, Harvey M, Himstreet J, et al. Opioid overdose education and naloxone distribution: Development of the Veterans Health Administration&#8217;s national program. J Am Pharm Assoc. 2017;57(2):S168&#8211;79.<pub-id pub-id-type="doi">10.1016/j.japh.2017.01.022</pub-id><pub-id pub-id-type="pmid">28292502</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><mixed-citation publication-type="other">Klinenberg E. Palaces for the people: how social infrastructure can help fight inequality, polarization, and the decline of civic life. Crown; 2018.</mixed-citation></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Mackin</surname><given-names>S</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>C</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>M</given-names></name><name name-style="western"><surname>Green</surname><given-names>TC</given-names></name></person-group><article-title>The Bronze Age of drug checking: barriers and facilitators to implementing advanced drug checking amidst police violence and COVID-19</article-title><source>Harm Reduct J</source><year>2022</year><volume>19</volume><issue>1</issue><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/s12954-022-00590-z</pub-id><pub-id pub-id-type="pmid">35120531</pub-id><pub-id pub-id-type="pmcid">PMC8814788</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Carroll JJ, Mackin S, Schmidt C, McKenzie M, Green TC. The Bronze Age of drug checking: barriers and facilitators to implementing advanced drug checking amidst police violence and COVID-19. Harm Reduct J. 2022;19(1):9.<pub-id pub-id-type="pmid">35120531</pub-id><pub-id pub-id-type="doi">10.1186/s12954-022-00590-z</pub-id><pub-id pub-id-type="pmcid">PMC8814788</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dasgupta</surname><given-names>N</given-names></name><name name-style="western"><surname>Figgatt</surname><given-names>MC</given-names></name></person-group><article-title>Invited commentary: drug checking for novel insights into the unregulated drug supply</article-title><source>Am J Epidemiol</source><year>2021</year><volume>191</volume><issue>2</issue><fpage>248</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1093/aje/kwab233</pub-id><pub-id pub-id-type="pmcid">PMC8824693</pub-id><pub-id pub-id-type="pmid">34528056</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Dasgupta N, Figgatt MC. Invited commentary: drug checking for novel insights into the unregulated drug supply. Am J Epidemiol. 2021;191(2):248&#8211;52.<pub-id pub-id-type="doi">10.1093/aje/kwab233</pub-id><pub-id pub-id-type="pmcid">PMC8824693</pub-id><pub-id pub-id-type="pmid">34528056</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malayala</surname><given-names>SV</given-names></name><name name-style="western"><surname>Papudesi</surname><given-names>BN</given-names></name><name name-style="western"><surname>Bobb</surname><given-names>R</given-names></name><name name-style="western"><surname>Wimbush</surname><given-names>A</given-names></name></person-group><article-title>Xylazine-induced skin ulcers in a person who injects drugs in Philadelphia, Pennsylvania, USA</article-title><source>Cureus.</source><year>2022</year><volume>14</volume><issue>8</issue><fpage>e28160</fpage><pub-id pub-id-type="pmid">36148197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.28160</pub-id><pub-id pub-id-type="pmcid">PMC9482722</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Malayala SV, Papudesi BN, Bobb R, Wimbush A. Xylazine-induced skin ulcers in a person who injects drugs in Philadelphia, Pennsylvania, USA. Cureus. 2022;14(8):e28160.<pub-id pub-id-type="pmid">36148197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.28160</pub-id><pub-id pub-id-type="pmcid">PMC9482722</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>RS</given-names></name><name name-style="western"><surname>Canver</surname><given-names>BR</given-names></name><name name-style="western"><surname>Sue</surname><given-names>KL</given-names></name><name name-style="western"><surname>Morford</surname><given-names>KL</given-names></name></person-group><article-title>Xylazine and overdoses: trends, concerns, and recommendations</article-title><source>Am J Public Health</source><year>2022</year><volume>112</volume><issue>8</issue><fpage>1212</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.2105/AJPH.2022.306881</pub-id><pub-id pub-id-type="pmid">35830662</pub-id><pub-id pub-id-type="pmcid">PMC9342814</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Alexander RS, Canver BR, Sue KL, Morford KL. Xylazine and overdoses: trends, concerns, and recommendations. Am J Public Health. 2022;112(8):1212&#8211;6.<pub-id pub-id-type="pmid">35830662</pub-id><pub-id pub-id-type="doi">10.2105/AJPH.2022.306881</pub-id><pub-id pub-id-type="pmcid">PMC9342814</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korn</surname><given-names>WR</given-names></name><name name-style="western"><surname>Stone</surname><given-names>MD</given-names></name><name name-style="western"><surname>Haviland</surname><given-names>KL</given-names></name><name name-style="western"><surname>Toohey</surname><given-names>JM</given-names></name><name name-style="western"><surname>Stickle</surname><given-names>DF</given-names></name></person-group><article-title>High prevalence of xylazine among fentanyl screen-positive urines from hospitalized patients, Philadelphia, 2021</article-title><source>Clin Chim Acta</source><year>2021</year><volume>521</volume><fpage>151</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2021.07.010</pub-id><pub-id pub-id-type="pmid">34265257</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Korn WR, Stone MD, Haviland KL, Toohey JM, Stickle DF. High prevalence of xylazine among fentanyl screen-positive urines from hospitalized patients, Philadelphia, 2021. Clin Chim Acta. 2021;521:151&#8211;4.<pub-id pub-id-type="pmid">34265257</pub-id><pub-id pub-id-type="doi">10.1016/j.cca.2021.07.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nolte</surname><given-names>K</given-names></name><name name-style="western"><surname>Romo</surname><given-names>E</given-names></name><name name-style="western"><surname>Stopka</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Drew</surname><given-names>A</given-names></name><name name-style="western"><surname>Dowd</surname><given-names>P</given-names></name><name name-style="western"><surname>Del Toro-Mejias</surname><given-names>L</given-names></name><etal/></person-group><article-title>&#8220;I've been to more of my friends&#8217; funerals than I've been to my friends&#8217; weddings&#8221;: witnessing and responding to overdose in rural Northern New England</article-title><source>J Rural Health</source><year>2023</year><volume>39</volume><issue>1</issue><fpage>197</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1111/jrh.12660</pub-id><pub-id pub-id-type="pmid">35301749</pub-id><pub-id pub-id-type="pmcid">PMC9481744</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Nolte K, Romo E, Stopka TJ, Drew A, Dowd P, Del Toro-Mejias L, et al. &#8220;I&#8217;ve been to more of my friends&#8217; funerals than I&#8217;ve been to my friends&#8217; weddings&#8221;: witnessing and responding to overdose in rural Northern New England. J Rural Health. 2023;39(1):197&#8211;211.<pub-id pub-id-type="pmid">35301749</pub-id><pub-id pub-id-type="doi">10.1111/jrh.12660</pub-id><pub-id pub-id-type="pmcid">PMC9481744</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><mixed-citation publication-type="other">Doe-Simkins M, Wheeler EJ, Figgatt MC, Jones TS, Bell A, Davidson PJ, et al. Naloxone buyers club: overlooked critical public health infrastructure for preventing overdose deaths. medRxiv. 2021:2021.11.14.21266221.</mixed-citation></ref><ref id="CR113"><label>113.</label><mixed-citation publication-type="other">Walters SM, Kerr J, Cano M, Earnshaw V, Link B. Intersectional stigma as a fundamental cause of health disparities: a case study of how drug use stigma intersecting with racism and xenophobia creates health inequities for Black and Hispanic persons who use drugs over time. Stigma Health. 2023.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/sah0000426</pub-id><pub-id pub-id-type="pmcid">PMC10516303</pub-id><pub-id pub-id-type="pmid">37744082</pub-id></mixed-citation></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>J</given-names></name><name name-style="western"><surname>Godvin</surname><given-names>M</given-names></name><name name-style="western"><surname>Shover</surname><given-names>CL</given-names></name><name name-style="western"><surname>Gone</surname><given-names>JP</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>H</given-names></name><name name-style="western"><surname>Schriger</surname><given-names>DL</given-names></name></person-group><article-title>Trends in drug overdose deaths among US Adolescents, January 2010 to June 2021</article-title><source>JAMA.</source><year>2022</year><volume>327</volume><issue>14</issue><fpage>1398</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.2847</pub-id><pub-id pub-id-type="pmid">35412573</pub-id><pub-id pub-id-type="pmcid">PMC9006103</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Friedman J, Godvin M, Shover CL, Gone JP, Hansen H, Schriger DL. Trends in drug overdose deaths among US Adolescents, January 2010 to June 2021. JAMA. 2022;327(14):1398&#8211;400.<pub-id pub-id-type="pmid">35412573</pub-id><pub-id pub-id-type="doi">10.1001/jama.2022.2847</pub-id><pub-id pub-id-type="pmcid">PMC9006103</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frank</surname><given-names>D</given-names></name><name name-style="western"><surname>Krawczyk</surname><given-names>N</given-names></name><name name-style="western"><surname>Arshonsky</surname><given-names>J</given-names></name><name name-style="western"><surname>Bragg</surname><given-names>MA</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Bunting</surname><given-names>AM</given-names></name></person-group><article-title>Covid-19-related changes to drug-selling networks and their effects on people who use illicit opioids</article-title><source>J Stud Alcohol Drugs</source><year>2023</year><volume>84</volume><fpage>222</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">36971722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15288/jsad.21-00438</pub-id><pub-id pub-id-type="pmcid">PMC10171252</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Frank D, Krawczyk N, Arshonsky J, Bragg MA, Friedman SR, Bunting AM. Covid-19-related changes to drug-selling networks and their effects on people who use illicit opioids. J Stud Alcohol Drugs. 2023;84:222&#8211;9.<pub-id pub-id-type="pmid">36971722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15288/jsad.21-00438</pub-id><pub-id pub-id-type="pmcid">PMC10171252</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhodes</surname><given-names>T</given-names></name></person-group><article-title>Risk environments and drug harms: a social science for harm reduction approach</article-title><source>Risk Environ Drug Harms</source><year>2009</year><volume>20</volume><issue>3</issue><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugpo.2008.10.003</pub-id><pub-id pub-id-type="pmid">19147339</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Risk Environ Drug Harms. 2009;20(3):193&#8211;201.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugpo.2008.10.003</pub-id><pub-id pub-id-type="pmid">19147339</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>